EDDRA Column. by Keane, Martin
On 18 May last President Mary McAleese
attended the 35th anniversary celebrations
of the Drug Treatment Centre Board
(DTCB) in the centre’s premises at Trinity
Court, Dublin. The centre is the longest-
established treatment service for drug
users in Ireland. President McAleese
welcomed the opportunity to thank the
Board, management and staff for their
effort over the last 35 years, and
acknowledged the number of lives the
centre had helped change: ‘Many
thousands of individuals and families have
cause to be grateful to you for the
treatment, counselling, support and hope
you have brought to lives skewed out of
kilter by addiction and drug abuse.’ She
noted that the approaches to treatment
ranged from an abstinence-only approach
to those including substitution therapy and services to support the families of
drug users. She said that this work had strengthened the individual, the family,
the community and the country. She commended individuals with problem drug
use for their courage in seeking and continuing in treatment. 
The National Drug Advisory and Treatment Service, now known as The Drug
Treatment Centre Board (DTCB), was established in 1969. The service was
originally located at the ‘Charitable Infirmary’, Jervis Street Hospital, Dublin 1,
which was established in 1718 as the first voluntary hospital in Ireland. The
current chairman of the DTCB, Mr Denis McCarthy, is from a long line of family
members who have held the chair of the Charitable Infirmary (now known as
the Charitable Infirmary Charitable Trust) since 1909. 
After the closure of Jervis Street Hospital in 1987, the Drug Treatment Centre
Board was set up by statutory instrument in 1988 and moved to new premises
at Trinity Court, 30-31 Pearse Street, Dublin 2. The centre has undergone
considerable change over the last 35 years and now has a staff of 110,
including doctors, nurses, psychotherapists, counsellors, family therapists,
childcare workers and laboratory staff. The DTCB provides on-site hepatitis C
testing and its laboratory is the largest specialist drug-screening facility in
Ireland, running in excess of one million tests annually. Inpatient detoxification
facilities are located at St Michael’s Ward, Beaumont Hospital, Dublin (10-bed
unit) and at Cuan Dara, Cherry Orchard Hospital, Dublin (17-bed unit). In
2002 there were circa 98,340 attendances at the DTCB.
President McAleese paid tribute to all those who had worked in the DTCB since
its earliest days, and continued, ‘I hope that on this day when we look back
over those years and see the difficult journey already successfully travelled, you
will find the self-confidence and renewed sense of vocation necessary to face
the awesome scale of what lies ahead.’ She stated that drug misuse has
become a part of our society and interventions to tackle this problem would be
required into the future. 
The Drug Treatment Centre Board provides a national Drug Analysis Laboratory
service which supports treatment policy, and monitors trends which supports
service planning and best practice in the treatment of drug misuse. (Damien
Walshe)
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Two recently published surveys examine prevalence
and patterns of both licit and illicit drug use in
post-primary school students in two health board
areas. Both survey are in fact follow-ups to earlier
surveys, so they provide a valuable insight into
drug use trends among young people. Each survey
will be discussed in turn in this article.
North Eastern Health Board survey
In November 2003 the
Department of Public Health
in the North Eastern Health
Board (NEHB) published the
results of a survey on
smoking, alcohol and drug
use among young people in
Counties Cavan, Monaghan,
Louth and Meath.1 The survey,
which was carried out in
2002, covered post-primary
school students aged 12–19 years. Using a
multistage stratified random sampling method, the
researchers surveyed a total of 1,426 students from
24 schools. The anonymous questionnaire used in
the survey (administered in the classroom setting
by a research officer) allowed comparisons with a
previous school survey in the NEHB in 1997.
In terms of illicit drug use, the survey found that 41
per cent of students had taken at least one illicit
drug2 in their lifetime. This was six per cent higher
than in the 1997 NEHB survey. In 2002, more girls
than boys reported that they had ever taken an
illicit drug (boys 41 per cent, girls 42 per cent),
compared to 1997 (boys 37 per cent, girls 32 per
cent). The large increase in lifetime prevalence of
any illicit drug for girls is a cause for concern since
it may reflect a growing willingness to experiment
with drugs.
Cannabis was the most commonly used illicit drug.
Thirty-one per cent of students reported using
cannabis at some stage in their lifetime, an increase
of over six per cent since the previous survey (see
table below). Just under thirteen per cent stated
that they had used cannabis in the past month, an
increase of over three per cent since 1997. 
Inhalants (glue, aerosols, etc.) were the second
most commonly used drugs in the north east
region. Lifetime and last month use of inhalants
was higher in 2002 than in 1997 (see table below).
Results from the 2002 survey suggest that younger
people were being approached with offers of drugs
more so than in 1997 and the person offering these
drugs was someone that their friends knew or was
their best or very good friend. This latter finding
highlights the potential influence of peers in the
use of drugs and points to the need for strategies
aimed at facilitating young people to identify and
resist peer influences.
Another notable finding from the survey was the
relationship that emerged between smoking,
alcohol consumption and illicit drug use. Regular
smokers (smoking at least one cigarette per day)
were more likely to have been offered illicit drugs
or to have taken an illicit drug: they were more
than six times more likely to report using an illicit
drug in the last month than were non-smokers. The
same pattern was also apparent among regular
drinkers (consuming one or more alcoholic drinks
per week), though not as strong as for regular
smokers. The report notes that these findings ‘point
to the potency of alcohol and, especially, tobacco
in illicit drug use and serve as support for
considering these substances as gateway drugs.’
The report goes on to stress that ‘gateway drugs do
not necessarily cause young people to use harder
drugs, but using these substances may set up
patterns of behaviour that may make it easier to
progress to using other drugs or may result in
young people frequenting places where they can
get or be offered illicit drugs’.
Mid-Western Health Board survey
In January 2004 the
Department of Public Health
in the Mid-Western Health
Board (MWHB) published a
survey of smoking, alcohol
and drug use by teenagers in
Counties Clare, Limerick and
Tipperary NR.3 The survey,
which was carried out in
2002, covered post-primary
school students aged 13-19
years. Using a multistage stratified random
sampling method, the researchers surveyed a total
of 2,297 students from 23 schools. The anonymous
questionnaire used in the survey (administered in
the classroom setting by the researchers or by
teachers) allowed comparisons with a previous
school survey in the MWHB in 1988. The report’s
findings are based on valid responses from 2,279
students.
In terms of drug use, the survey found that 39 per
cent of students had used at least one drug4 in their
lifetime. This was almost ten per cent higher than
in the 1998 MWHB survey. Cannabis was the most
commonly used illicit drug: 29 per cent of students
reported using cannabis at some stage in their
lifetime, again an increase of almost ten per cent
since the previous survey (see table below). Fifteen
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Cannabis use
During lifetime
During last month
NEHB (1997)
%
24.6
9.4
NEHB (2002)
%
31.0
12.8
Inhalant use
During lifetime
During last month
NEHB (1997)
%
18.9
2.0
NEHB (2002)
%
21.8
2.5
Results from the
2002 survey
suggest that
younger people
were being
approached with
offers of drugs
more so than in
1997
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per cent of students stated that they had used
cannabis in the month prior to the survey, an
increase of seven per cent since 1998.
Inhalants (glue, aerosols, etc.) were the second
most commonly used drugs in the mid-west region
and both lifetime and last month use increased
since 1998 (see table below). 
Most students in the 2002 survey indicated that
cannabis was the first illicit drug they had used,
that a friend was the main source of this drug and
that ‘curiosity’ was the main reason why they chose
to experiment with drugs. In 1998 the most
common reason for experimenting with drugs was
‘everyone else does it’. These findings highlight the
potential influence of peers in the first use of drugs.
In terms of alcohol use in the MWHB, lifetime
prevalence rates for alcohol consumption were
higher in the 2002 than in the 1998 survey (90 per
cent compared to 82 per cent). However, the
current (last month) drinking rate in 2002 was
lower than in the previous survey (62 per cent
compared to 68 per cent). While the drop in
current alcohol consumption is encouraging, it was
found that the rates of both lifetime and last month
alcohol use were higher among girls than boys.
This was a reversal of the pattern found in the 1998
survey and is a cause of concern.
The most popular alcoholic drinks with male
students were beer and cider, while females
preferred alcopops and spirit-based drinks. When
asked about drinking five or more drinks in a row in
the past 30 days (binge drinking), 44 per cent of
students reported having done so; 23 per cent of
students reported indulging in binge drinking on
three or more occasions during the past 30 days,
which is regarding internationally as ‘rather
intensive alcohol consumption’.5 The frequency of
binge drinking increased with age. The report notes
that alcohol use by school-going teenagers in the
mid-west region is still at ‘undesirable levels’
particularly in light of the fact that 85 per cent of
students were under the legal drinking age.
(Hamish Sinclair)
The reports, Teenage smoking, alcohol and drug use
in the Mid-Western Health Board region 2002 and
Smoking, alcohol & drug use among young people,
are both available on the National Documentation
Centre website at www.hrb.ie/ndc
1. Flanagan E, Bedford D, O’Farrell A and Howell F (2003)
Smoking, alcohol & drug use among young people. North
Eastern Health Board: Department of Public Health.
2. Includes cannabis, inhalants, ecstasy, speed, magic
mushrooms, cough syrup, cocaine, LSD, heroin and
barbiturates (note: not all these drugs are illicit).
3. Kelleher K, Cowley H and Houghton F (2004) Teenage
smoking, alcohol and drug use in the Mid-Western Health
Board region 2002. Mid-Western Health Board:
Department of Public Health.
4. Includes cannabis, inhalants, ecstasy, magic
mushrooms, tranquillisers without prescription,
amphetamines, crack, cocaine, heroin and LSD. 
5. Hibell B et al. (2000) The 1999 ESPAD Report. Alcohol
and other drug use among students in 30 European
countries. Stockholm: The Swedish Council for
Information on Alcohol and Other Drugs (CAN), Co-
operation Group to Combat Drug Abuse and illicit
Trafficking in Drugs (Pompidou Group) at the Council
of Europe.
Cannabis use
During lifetime
During last month
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%
19.0
8.4
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%
28.6
15.4
Inhalant use
During lifetime
During last month
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%
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2.7
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A key performance indicator under the
prevention pillar of the National Drugs
Strategy 2001 – 2008 is to bring drug misuse
by school-goers to below the EU average
and, as a first step, to reduce the level of
substance misuse reported to the European
School Survey Project on Alcohol and Other
Drugs (ESPAD) by school-goers by 15 per
cent by 2003 and by 25 per cent by 2007
(based on 1999 ESPAD levels). The results of
the 2003 ESPAD survey should be available
later this year.
Young people debate drug and 
alcohol abuse
CityWide Drugs Crisis Campaign 
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In November 2003 the annual Dáil na nÓg,1 or
Irish Youth Parliament, debated drug and alcohol
abuse. The delegates concluded:
■ We need more facilities, leisure centres, discos,
youth clubs and other alcohol-free activities.
■ Information and education is too late or not at
all – we need campaigns on drugs and alcohol
from primary school up.
■ We want advertising to highlight the dangers of
drug and alcohol abuse.
■ We need support to overcome peer-pressure.
■ Alcohol is part of our culture – adults need to
change too. 
The Minster for Children, Brian Lenihan TD, told
the delegates that the lack of non-pub
entertainment facilities for teenagers was a major
national issue and guaranteed delegates that a
recreation policy for 12–18-year-olds would be
prepared by the National Children’s Office (NCO).2
As a preliminary step, the NCO called for proposals
for research contributing to the development of a
recreation and leisure policy for young people aged
13–17 years. The NCO has also called for research
proposals in relation to youth homelessness in
Ireland. These calls for research proposals closed on
12 May 2004. (Brigid Pike)
1 Arising out of the National Children’s Strategy and in
line with Article 12 (1) of the UN Convention on the
Rights of the Child, Dáil na nÓg, the Irish Youth
Parliament, was established in 2001 to provide an
annual national forum where young people and children
can raise and debate issues of concern, under the
auspices of the Minister for Children. A report on the
outcome of Dáil na nÓg is submitted to the Cabinet
Committee on Children, which is chaired by the
Taoiseach. For further information see the Dáil na nÓg
website at www.dailnanog.ie 
2 The National Children's Office (NCO) was established in
2001 to improve all aspects of children's lives by leading
and supporting the implementation of the National
Children’s Strategy – Our Children Their Lives. For
further information see the NCO website at www.nco.ie 
In March 2004, CityWide
Drugs Crisis Campaign
published a report entitled
Cocaine in local communities:
survey of community drug
projects.1 This survey was
carried out in response to the
growing concern expressed by
community groups across
Dublin in relation to the
emerging cocaine problem in
many parts of the city. The authors surveyed
community drug projects to establish whether
cocaine users were being treated by local services
and, if so, what services were offered to them and
what additional services needed to be developed.
Questionnaires were sent to 59 community drug
projects requesting information about cocaine use
among clients of services and within communities.
Although the response rate was low (46 per cent), the
projects that participated in the study represented
each task force area within Greater Dublin and that of
Dun Laoghaire–Rathdown. The non-respondents may
manage drug projects where cocaine use is not a
problem, and therefore did not complete the
questionnaire, leading to a reporting bias.
Twenty-five (93 per cent) of the 27 respondents
claimed that some existing clients were using
cocaine. Three-quarters of the project participants
estimated that between 10 and 50 per cent of their
clients were using cocaine. However, it is unclear
from the report whether or not this cocaine use
was problematic. All of the project workers who
took part in the study said that they were aware of
people living in their communities who were using
cocaine but not currently seeking treatment at their
services. Fifty-eight per cent of the project workers
noted that cocaine use was on the increase among
young people. Almost one-third of the respondents
claimed that cocaine was cheap and easily
available, while one in four could identify where
cocaine was being sold. Two project participants
noted that there was a significant difference in the
price of cocaine being sold in different parts of
their communities. Three stated that heroin
supplies were decreasing in their areas while
cocaine was on the increase. One-fifth of the
respondents viewed cocaine as a social drug that
was being used by people who had not used drugs
in the past.
The report outlines the implications cocaine has for
the users and their families and for the wider
community. 
Individuals
■ Fifty-two per cent of the project workers
reported that cocaine use caused clients to
become aggressive and agitated, resulting in
difficulties for staff. 
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CityWide Drugs Crisis Campaign
(continued)
■ Almost two-fifths of the respondents reported
that the ‘high’ from cocaine does not last very
long; clients therefore use cocaine more
frequently, which has cost implications. 
■ Fifteen per cent of project workers reported that
clients were becoming involved in crime in order
to cover the costs of their cocaine use. 
■ Twenty-two per cent of the participants reported
that clients presented with mental health
problems. 
■ A number of project workers, particularly those in
the south inner city and Ballyfermot, reported
that clients injecting cocaine combined with
heroin were developing deep vein thrombosis
(DVT) and abscesses. 
Families 
■ Thirty per cent claimed that parents of cocaine
users were extremely worried and unsure of how
to deal with the problem. 
■ Project respondents in Dublin 8 claimed that
families had no option but to leave the area
because of cocaine-related debt or anti-social
behaviour. 
■ Some project workers reported an increase in the
number of young people forced to leave home
because of their cocaine use. 
■ Respondents reported that cocaine can also have
a negative impact on the children of users; for
example, in the Dublin 8 area a small number of
children had been put into care because of their
parents’ excessive cocaine use.
Communities (Figure A)
■ Fifty-eight per cent of project workers reported
increases in petty crime, dealing and other anti-
social behaviour within their community, 
■ Eight per cent of project staff cited recreational
cocaine use as causing work-related problems for
a number of people living in the area. 
The lack of services available to cocaine users was
of particular concern to those who participated in
the study. According to the report, almost one in
five respondents said that they had no services for
cocaine users; however, the majority of projects did
provide some services. These included:
acupuncture, yoga, reiki, relaxation methods,
Indian massage, and home detoxification through
acupuncture and acupressure. Almost 60 per cent
of the projects provided counselling, while 45 per
cent provided harm reduction services specifically
for cocaine users. Fourteen per cent provided
practical support, such as laundry, bathing facilities
and nursing care. Half of the project workers
claimed that they were not aware of any other
service available to treat cocaine use in their area.
Project workers stated that they would be
interested in providing:
■ Alternative therapies specifically for cocaine users;
■ Cocaine-specific education programmes;
■ Respite for cocaine users;
■ Detoxification programmes.
However, in order for such services to be
developed, project workers felt that they would
need additional training and an increase in staffing
and funding, and evidence of political will to tackle
the issue. The findings of this study support the
findings reported by the National Advisory
Committee on Drugs in its overview of cocaine use
in Ireland.s (Fionnola Kelly)
1. CityWide Drugs Crisis Campaign (2004) Cocaine in local
communities: survey of community drug projects. Dublin:
CityWide Drugs Crisis Campaign.
2. National Advisory Committee on Drugs (2003) An overview
of cocaine use in Ireland. Dublin: The Stationery Office. 
8%
11%
58%
16%
8%
Figure A Negative experiences of cocaine
use on local communities reported by
project respondents
Source: CityWide Drugs Crisis Campaign 
March 2004  
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In early 2004 The Katharine Howard Foundation
published a report examining the issue of
homelessness among young men in the context of
the wider issue of marginalisation among men in
contemporary Ireland. Entitled Young men on the
margins, the report was written by researchers from
the Social Science Research Centre at University
College Dublin, with Anne Cleary as project
director. One of the main objectives of the research
was to gain an understanding of how and why
some men end up and remain homeless.
Using a qualitative approach, the researchers
conducted in-depth semi-structured interviews over
a period of two months with twenty men aged
18–30 years attending a drop-in centre for
homeless men in Dublin. A high prevalence of
substance misuse was found in this sample of men.
Thirteen participants were, or had been, addicted
to heroin, seven were current intravenous (IV)
heroin users, six were on methadone maintenance
programmes, and one of these was also addicted
to alcohol. Two men were described as having
alcohol problems. One participant had been
addicted to ecstasy, but was now clear, and one
young man was a heavy cannabis user. Several
participants reported polydrug use, using a mixture
of benzodiazepines, sleeping tablets, Valium,
alcohol and heroin. 
The majority of participants reported engaging in
drug use prior to becoming homeless and some
reported that this behaviour had caused them to
become homeless. Many explained that they were
removed from the home by relatives unwilling to
endure their anti-social behaviour around drug use
and criminal activity. Some criminal activity was
directly related to securing money to buy drugs.
The experience of homelessness led to more
chaotic drug use for some, with progression to
heroin use tending to follow their becoming
homeless. A consequence of this progression was
that drug use now became the main obstacle for
most participants wishing to move out of
homelessness. In addition, a number of participants
had experience of overdosing leading to
hospitalisation. However, this did not deter them
from using drugs.
Many participants had experience of trying to stop
using drugs; 16 men reported undergoing some
form of detoxification for their drug use. However,
criticism was voiced of existing drug treatment
services, long waiting lists and difficulty in securing
treatment without a fixed address were cited.
These were viewed as major barriers to progression
out of homelessness. In addition, some participants
expressed concern about substituting methadone
maintenance for their heroin addiction, as they had
a negative perception of the symptoms of
withdrawal from methadone. 
A positive message for policy makers and
practitioners emerged from the research. Most
participants remained orientated towards
important social goals. For example, many
expressed their need to regain 'normality' in their
lives through the restoration of broken relationships
with ex-girlfriends and their hopes of becoming
fathers. This is an important theme to emerge from
this research, for it indicates the value of some
form of family unit to marginalised men who are
homeless and using drugs. For policy makers and
practitioners alike, the restoration of damaged
family bonds among marginalised men with drug
problems needs to be discussed alongside other
social inclusion measures such as accommodation,
education/training and employment initiatives. 
The current report is a valuable addition to the
existing research on drug use among the homeless.
For example, Houghton and Hickey2 and Halpenny
et al.,3 looking at homeless families in emergency
accommodation, also found that drug misuse was
reported to be a major contributory factor to
becoming homeless in the first instance. Smith et
al.4 found that homeless women in emergency
accommodation reported engaging in a high level
of polydrug use, including injecting heroin, during
their homeless experience. Although these studies
focused on different groups of participants, drug
misuse as a major contributor to becoming and
remaining homeless is clearly a dominant theme.
(Martin Keane)
1. Cleary A, Corbett M, Galvin M and Wall J (2004)
Young men on the margins. Dublin: Katharine
Howard Foundation. 
2. Houghton FT and Hickey C (2000) Focusing on
B&Bs: the unacceptable growth of emergency B&B
placement in Dublin. Dublin: Focus Ireland.
3. Halpenny AM, Keogh AF and Gilligan R (2002) A
place for families? Children in families living in
emergency accommodation. Dublin: Homeless
Agency. 
4. Smith M, McGee H and Shannon W (2001) One
hundred homeless women: health status and
health service use of homeless women and their
children in Dublin. Dublin: Royal College of
Surgeons in Ireland. 
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The geographical distribution of drug
use in Ireland
On 19 April the National Advisory Committee on
Drugs (NACD) and the Department of Health,
Social Services and Public Safety (Northern Ireland)
published jointly the second bulletin of results from
the 2002/2003 all-Ireland general population drug
prevalence survey. Bulletin 2 presented drug,
alcohol and tobacco use rates for each Health
Board in Ireland and Health and Social Services
Board in Northern Ireland. Minister of State at the
Department of Community, Rural and Gaeltacht
Affairs with responsibility for drugs strategy, Mr
Noel Ahern TD, launched the findings.
The Irish drug prevalence survey followed best
practice guidelines recommended by the European
Monitoring Centre for Drugs and Drug Addiction
(EMCDDA). The questionnaire, based on the
‘European Model Questionnaire’, was administered
through face-to-face interviews with respondents
aged between 15 and 64 years normally resident in
households in Ireland and Northern Ireland. The
survey was undertaken by MORI MRC during late
2002 and early 2003. The final achieved sample
was 4,925 in Ireland and 3,517 in Northern Ireland.
This represents a response rate of 70 per cent in
Ireland and 63 per cent in Northern Ireland.
One interesting finding from the publication is that
the pattern of current cannabis use (used in last 30
days) among young adults (15–34 years) by health
board area in Ireland displays a clear east to west
gradient (see map). 
Drug prevalence surveys of the general population
are important in that they can shed light on the
patterns of drug use, both demographically and
geographically and, if repeated, can track changes
over time. They help to increase our understanding
of drug use, and to formulate and evaluate drug
policies. They also enable informed international
comparisons provided countries conduct surveys in
a comparable manner.
The survey was commissioned by the National
Advisory Committee on Drugs (NACD) and the
Drugs and Alcohol Information and Research Unit
(DAIRU) within the Department of Health, Social
Services and Public Safety in Northern Ireland.
(Hamish Sinclair)
Bulletin 2 of the 2002/2003 Drug Prevalence
Survey is available on the NACD website at
www.nacd.ie 
EMCDDA guidelines for drug prevalence surveys are
available on the EMCDDA website at
www.emcdda.eu.int
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Brennan and colleagues1 published a paper entitled
‘Epidemiology of Hepatitis C in Ireland’ in EPI-
INSIGHT in May 2004. The authors collated
information on hepatitis C from a variety of
sources. In Ireland there is no estimate of the
prevalence of hepatitis C among the general
population. According to the Irish Blood
Transfusion Service,1 the prevalence of hepatitis C
among new donors decreased from 0.06 per cent
in 1997 to 0.01 per cent in 2004; this decrease
reflects changes in eligibility criteria for blood
donation rather than a true decrease among the
population. The prevalence of HIV and hepatitis B
among the general population was three times that
among new blood donors living in Dublin. There is
no reason not to believe that a similar risk ratio
between new blood donors and the general
population exists for hepatitis C.
The prevalence estimates among injecting drug
users attending community-based drug services
range between 52 per cent and 84 per cent (Table
1). 2–6 Hepatitis C is endemic among injectors in
prison; the prevalence of hepatitis C antibodies
among injector-inmates and entrants was 81 per
cent7 and 72 per cent8 respectively (Table 1). 
Allwright et al.7 and Long et al.8 (2001) reported
that injecting drug use was the most important risk
factor for hepatitis C. Allwright et al.7 (2000) and
Smyth et al.9 (2003) reported that spending time in
prison prior to testing was associated with an
increased risk of testing positive for hepatitis C
antibodies. Length of time injecting appears to be
strongly associated with contracting the infection. 2,3,4,7
For example, among drug users attending Trinity
Court Drug Treatment Centre the prevalence of
hepatitis C was 52 per cent among those injecting
for less than 25 months, compared to 84 per cent
among those injecting for 25 months or more.
Also, the prevalence of hepatitis C was 65 per cent
among prison inmates injecting for less than 36
months, compared to 85 per cent among those
injecting for 36 months or more.2 Injecting
practices such as injecting frequency and sharing
needles were also associated with testing positive
for hepatitis C.7,8
Epidemiology of hepatitis C among drug
users in Ireland
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Year
published
and authors
1995
Smyth 
et al. 2
1998
Smyth 
et al. 3
1999
Smith 
et al. 4
Study Design
Old and new
attendees registered
at Trinity Court Drug
Treatment Centre,
Dublin, August 1992
to August 1993
New attendees
registered at Trinity
Court Drug Treatment
Centre, Dublin
between 1992 and
1997
1993 
1994 
1995 
1996 
1997 
Between 1992 and
1997, new attendees
registered at Trinity
Court Drug Treatment
Centre, Dublin
Study population and
sample size
272 injectors living in
Dublin City
735 injectors living in
Dublin City
160
177
152
118
116
353 injectors living in
Dublin and injecting
less than 25 months
Study Findings
Overall prevalence of
anti-HCVa was 84%. 
Overall prevalence of
anti-HCV was 61.8%.
67.6%
61.0%
63.2%
52.5%
62.1%
Prevalence of anti-
HCV was 52.1%.
Method to ascertain
status
Status ascertained
from serum
Status ascertained
from serum
Status ascertained
from serum
Table 1   Review of studies estimating the prevalence of hepatitis C among
injecting drug users in Ireland
Taken together,
these data
suggest hepatitis
C is endemic
among injecting
drug users and it
has serious
health
consequences
which can be
seen in both
morbidity and
mortality
statistics
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Since 1 January 2004 there is a statutory
requirement to notify both laboratory and clinical
diagnosis of hepatitis C.10 Up to the end of 2003,
there was a statutory requirement to notify clinical
cases of viral hepatitis type unspecified (also known
as non A and non B) to the public health
departments in each health board. Since mid-2000,
the type of hepatitis was notified when hepatitis C
was the cause of hepatitis and it was observed that
the vast majority of cases had this virus type.1 From
2001 to 2003, just over 80 cases of hepatitis C were
notified each year. In 2002, approximately 85 new
cases of hepatitis C were reported to public health
departments through the clinical notification
system, while the National Virus Reference
Laboratory reported 1,233 new hepatitis C antibody
cases in the same year. This suggests serious under-
reporting of clinical cases, which should be rectified
under the new statutory instrument. The notification
system does not allow us to identify risk factors so it
is unclear how many of these cases were injecting
drug users. This indicates the need for an extended
notification process for hepatitis C. 
Between 1992 and 1998, Smyth et al. estimated
the incidence of hepatitis C among 100 injecting
drug users who had an initial negative test and a
repeat test within 24 months.9 The authors
reported that the incidence of hepatitis C was 66
per 100 person years (95% CI 51 to 84 per 100
person years); this is 30 per cent higher than
estimates reported in injecting drug users living in
other countries.
There were 6,085 discharges from acute hospitals
with hepatitis C as a primary or secondary diagnosis
recorded by the Hospital In-Patient Enquiry
Scheme.1 This scheme is an event- based register 
so cases may be represented more than once. 
Epidemiology of hepatitis C among drug
users in Ireland (continued)
Year
published
and authors
2000
Cullen 
et al. 5
2001
Fitzgerald 
et al. 6
2000
Allwright 
et al. 7
2001
Long 
et al. 8
Study Design
Review of records of
clients attending
methadone
substitution clinics in
a general practice
setting
Review of client
records attending 5
methadone clinics in
Dublin
Cross-sectional survey
Cross-sectional survey
Study population and
sample size
Injectors and non-
injectors (78) living in
Dublin, Kildare &
Wicklow 535 (of
whom 372 had their
hepatitis C status
recorded)
99, including injectors
and non-injectors
living in Dublin City
Prison inmates
Of whom 509 were
injectors
Prison entrants
Of whom 173 were
injectors
Study Findings
Of those who had
hepatitis C status
recorded in their
clinical notes, 72.6%
had a documented
hepatitis C positive
status. 
The primary objective
of this study was not
to assess prevalence
of HIV.
Of those who had
hepatitis C status
recorded in their
clinical notes, 79%
had a documented
anti-HCV positive
status.
81.3% tested positive
for anti-HCV.
71.7% tested positive
for anti-HCV.
Method to ascertain
status
Clinical records
Status ascertained
from laboratory
reports or clinical
notes
Status ascertained
from oral fluid
Status ascertained
from oral fluid
Table 1 (continued) Review of studies estimating the prevalence of hepatitis C
among injecting drug users in Ireland
a Following initial infection with hepatitis C, antibodies to this virus develop on average three months after infection but
may take up to six months to develop. The presence of hepatitis C antibodies (anti-HCV) indicates either previous or
current infection. 
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Epidemiology of hepatitis C among drug
users in Ireland (continued)
Outreach work
Of the 6,085 cases: 
■ 18 per cent had hepatitis C as a primary
diagnosis; 
■ 57 per cent had chronic hepatitis C;
■ 21 per cent had a diagnosis of problem 
opiate use; 
■ 7 per cent also had a diagnosis of hepatitis B
recorded;
■ 24 per cent also had a diagnosis of HIV/AIDS
recorded;
■ 11 per cent had a diagnosis of chronic liver
disease or sequelae;
■ 0.4 per cent had a diagnosis of liver cancer.
These data suggest the existence of co-morbidity
between blood-borne viruses and the damage that
hepatitis C can do to the liver.  
Brennan and colleagues1 requested the Central
Statistics Office to select cases where the primary
cause of death was hepatitis ICD 9 category 070.4,
070.5 or 070.6. This allowed the authors to
calculate the number of deaths with a primary
diagnosis of hepatitis C using the diagnoses
hepatitis ‘other specified’ or ‘unspecified’ as proxy
diagnoses. Fifty persons died as a result of hepatitis
C between 1995 and 2002. Up to 2001, the
numbers for each year fluctuated between three
and seven cases, with a rise to 15 cases in 2003.
The main risk factors for hepatitis C cannot be
identified accurately through mortality data held by
the Central Statistics Office. This suggests the need
for a special register to record the contribution of
hepatitis C to premature mortality among injecting
drug users. 
Taken together, these data suggest hepatitis C is
endemic among injecting drug users and it has
serious health consequences which can be seen in
both morbidity and mortality statistics. (Jean Long)
1. Brennan A, Thornton L, Connell J, O’Neill W,
O’Riordan J (2004) Epidemiology of Hepatitis C
infection in Ireland. EPI-INSIGHT, 5 (5):2-4. 
2. Smyth R, Keenan E and O'Connor JJ (1995) Hepatitis
C infection among injecting drug users attending the
national drug treatment centre. Irish Journal of Medical
Science, 165(4): 267–268.
3. Smyth R, Keenan E and O'Connor JJ (1998) Blood-
borne viral infection in Irish injecting drug users.
Addiction, 93(11): 1649–1656.
4. Smyth B, Keenan E and O'Connor JJ (1999 a)
Evaluation of the impact of Dublin's expanded harm-
reduction programme on prevalence of hepatitis C
among short term injecting drug users. Journal of
Epidemiology and Community Health, 53: 434–435.
5. Cullen W, Bury G, Barry J and O’Kelly F (2000) Drug
users attending general practice in the Eastern
Regional Health Authority area. Irish Medical Journal,
93(7): 214–217.
6. Fitzgerald M, Barry J, O'Sullivan P and Thornton L
(2001) Blood-borne infections in Dublin's opiate users.
Irish Journal of Medical Science, 170(1): 32–34.
7. Allwright S, Bradley F, Long J, Barry J, Thornton L and
Parry JV (2000) Prevalence of antibodies to hepatitis
B, hepatitis C and HIV and risk factors in Irish
prisoners: results of a national cross-sectional survey.
British Medical Journal, 321: 78–82.
8. Long J, Allwright S, Barry J, Reaper-Reynolds S,
Thornton L, Bradley F and Parry JV (2001) Prevalence
of antibodies to hepatitis B, hepatitis C and HIV and
risk factors in entrants to Irish prisons: a national
survey. British Medical Journal, 323: 1209–1213. 
9. Smyth B, O'Connor JJ, Barry J, Keenan E (2003)
Retrospective cohort study examining incidence of
HIV and hepatitis C infection among injecting drug
users in Dublin. Journal of Epidemiology and
Community Health, 57: 310–311. 
10. Changes to Notification of Infectious Diseases
(January 2003) Accessed at:
www.ndsc.ie/IDStatistics/ChangestoNotificationofInfec
tiousDiseases/ 
The paper ‘Epidemiology of Hepatitis C in Ireland’
is available on the National Disease Surveillance
Centre website at:
www.ndsc.ie/Publications/Hepatitis-viral/HepatitisC
Definition
The outreach worker is the link person between
drug users and harm minimisation services. 
The assumption behind outreach work is that
individuals are ‘out there' using drugs and not in
contact with existing harm minimisation or drug
treatment services. These include young 'chaotic
drug users', homeless drug users and drug users
involved in the sex industry. Outreach work
targeting individuals engaging with illicit drug use
has tended to focus on these 'hard-to-reach' and
'hidden' populations of drug users. When outreach
work was first introduced, the rationale
underpinning this work was that users, once
reached, could be persuaded to engage with
treatment services. Over time, it became obvious
that ‘the abstinence approach to treatment’ was not
always feasible for individuals as a first treatment
option. Currently, outreach workers place a strong
emphasis on ‘a harm minimisation approach to drug
use’. According to Korf et al. (1999)1
Outreach work in the drug field is a proactive
method used by professionals and trained
volunteers or peers to contact drug users. Its
drugnet Ireland
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aims are to inform them about the risks
associated with drug taking, to support them
in reducing or eliminating such risks, and/or to
help them improve their physical and
psychosocial circumstances through individual
or collective means. (p.85)
Evaluation of outreach work in
Ireland
There have been two formal reviews of outreach
work with drug users in Ireland. Each review
examined different but complementary aspects of
outreach services. Between June and December
2002, Bunning2 examined the policy, planning and
organisation of the services; between December
2000 and October 2001, Corr,3 in partnership with
outreach workers, reviewed outreach activities and
investigated the immediate effects of these activities
on drug-users’ practice. The Eastern Regional
Health Authority (ERHA) commissioned the
evaluation done by Bunning in response to Action
64 of the National Drugs Strategy, while Corr at
Merchants Quay Ireland (MQI) completed an
internal evaluation.  
The main objective of Bunning’s review was to
examine the role and functioning of outreach
services in the drugs and AIDS services in the
eastern region. This involved reviewing the
outreach service with respect to strategic aims and
objectives, general management, service provision,
quality control and monitoring systems. The
reviewer contacted: clients (20), outreach workers
(20), senior outreach workers (4), representatives
from community projects (10), and persons
employed by the area health boards (21) whose
work had links with outreach services. The review
was carried out using the following methods: 
■ Observation of outreach workers during their
day-to-day activities, which included home visits,
street work, and community-based projects; 
■ Group interviews with management of the
addiction services, health professionals and
community groups; 
■ Individual interviews with outreach workers and
clients;
■ Focus groups with senior outreach workers;
■ Feedback sessions with steering committee. 
The reviewer found that there was good
commitment from staff across the addiction
services to participating in the review. Outreach
workers conceptualised their activities as: 
Initiating and maintaining contact with those
who are not in contact with services, relating
to them in an open manner and observing
what is going on in the drug scene within
different local communities 
(Bunning 2003: 10) 
The reviewer reported that, due to the
unprecedented expansion in drug treatment
services in the ERHA over the last four years, a lack
of strategic planning for outreach had resulted. This
meant that outreach work was out of focus and
that outreach workers carried out a broad range of
tasks that were often based on personal preferences
and skills, rather than on clear policy choices or
guidelines. 
The recommendations for the future development
of outreach services within the eastern region
include: 
■ Define a clear mission statement;
■ Prioritise primary and secondary tasks based on
an allocation of time;
■ Develop wider needle-exchange networks that
include options such as pharmacies and vending
machines;
■ Develop clear links between clinical staff,
outreach workers and clients; 
■ Formalise the role of outreach workers as
advocates for the clients;
■ Organise seminars to stimulate peer education,
knowledge transfer and up-skilling;
■ Set up an outreach association that will work
towards the professional development of
outreach staff;
■ Provide management training to senior outreach
workers;
■ Develop a monitoring system that includes
quantitative and qualitative indicators;
■ Create a steering group to explore innovative
approaches to outreach. 
The second evaluation was conducted by Corr of
the outreach service within Merchants Quay Ireland
(MQI). The outreach service was established in the
late nineties to reduce the levels of drug-related
public nuisance in the immediate locality. MQI is
located in the south-west inner city of Dublin. The
outreach service targets chaotic drug users in the
locality and seeks to change their behaviour in the
community through one-to-one interactions. The
outreach teams work in pairs to ensure workers’
and clients’ safety. In order to minimise danger, the
outreach workers carry mobile phones and identity
cards. The majority of the outreach work is done on
the streets. The team works on building rapport
with clients and providing information on health
issues and accommodation. The team uses
motivational interviewing techniques to promote
safer drug-using practices among clients. The ERHA
and Dublin City Council fund the service jointly. 
A combination of quantitative and qualitative
methods was used to evaluate the MQI service.
Between December 2000 and October 2001,
outreach workers completed ‘contact sheets’ on all
Outreach work (continued) 
The data
presented in this
document
indicate that
outreach workers
were successful in
contacting hard-
to-reach drug
users
clients met each day. In order to place the
quantitative data collected in context with the day-
to-day realities of outreach work, two outreach
workers participated in in-depth interviews. During
the 10-month evaluation period, a total of 262
clients were contacted at least once. In total, there
were 587 separate contacts with clients; 163 (62%)
were contacted once only and 99 (38%) were re-
contacted an average of four times. Of those
contacted, 31 per cent were female, 52 per cent
were aged 24 years or under and 27 per cent were
first-time contacts. Three-quarters were homeless at
some point during the year. Overall, 88 per cent
reported using drugs (other than alcohol) and 96
per cent reported the streets as their most popular
location for taking drugs. Of those using drugs, 79
per cent were using heroin. During the 10-month
period, the outreach workers collected and
disposed of 2,741 needles. The outreach workers
reported that among the 99 clients who were met
more than once, almost one-fifth had changed to
safer drug-using practices and half had adopted
less safe practices. In addition, the team reported
that approximately fifteen per cent of clients
contacted were referred to other drug treatment
services. The data presented in this document
indicate that outreach workers were successful in
contacting hard-to-reach drug users as a large
proportion were homeless and half had never been
in contact with drug treatment services. 
Taken together, these evaluations highlight the
need to develop the capacity of outreach staff and
enhance the general management of the services.
At the same time, the documents present the
essential role of outreach workers and the positive
outcomes of their work, such as success in locating
hard-to-reach populations, an increase in numbers
using safer injecting practices and modest numbers
referred into treatment. However, it may be useful
to explore why 50 per cent of those participating
in the Merchants Quay Ireland study developed
additional unsafe injecting practices despite
receiving safe injecting information. (Jean Long and
Martin Keane)
1. Korf D, Riper H, Freeman M, Lewis R, Grant I, Jacob E,
Mougin M and Nilson M (1999) Outreach work among
drug users in Europe: concepts, practice and terminology.
Lisbon: EMCDDA. 
2. Bunning E (2003) Outreach in Focus: review of outreach
services in the Drugs/AIDS service in the eastern region.
Dublin: ERHA unpublished report.
3. Corr C (2004) ‘Engaging the hard-to-reach: an
evaluation of an outreach service’. In Pieces of the
jigsaw. Dublin: Merchants Quay Ireland. 
Pieces of the jigsaw is available from Merchants Quay
Ireland (see ‘Recent Publications’ section for details). 
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Drug consumption rooms
In March 2004, the European Monitoring Centre
for Drugs and Drug Addiction (EMCDDA)
published a review of the evidence base for the
introduction of consumptions rooms as part of a
harm reduction strategy. 
Definition
Consumption rooms are protected places for the
hygienic consumption of pre-obtained drugs in a
non-judgemental environment and under the
supervision of trained health and social care staff.
They comprise a highly specialised drugs service
within a wider network of services for drug users.
Consumption rooms are official services, funded
from local or regional budgets or by voluntary
organisations. They are distinct from illegal
‘shooting galleries’, which are run for profit by
drug dealers, as well as from consumption facilities
provided within the framework of drug prescription
programmes, where drugs are supplied to users.
Rationale and objective
Dagmar Hedrich1 at the EMCDDA reviewed the
available literature on consumption rooms. She
reviewed 143 articles, written in several European
languages, from published and grey literature. The
overall rationale for consumption rooms is to reach
and address the problems of specific, high-risk
populations of drug users, especially injectors and
those who consume in public. These groups have
important healthcare needs that are often not met
by other services, and pose problems for local
communities that have not been solved through
other responses by drug services, social services or
law enforcement.
According to Hedrich’s review, the specific
objectives of consumption rooms are: 
■ to establish contact with difficult to reach
populations;
■ to provide a safe and hygienic
environment for drug consumption, and
injecting drug use in particular;
■ to reduce mortality and morbidity
associated with drug use including
overdose, as well as transmission of HIV,
hepatitis, and bacterial infections;
■ to promote other social, health and drug
treatment services;
■ to reduce public drug use and associated
nuisance. 
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Availability and house rules
The author reported that in Europe there are 62
consumption rooms located in 36 cities in four
countries, namely, Switzerland, the Netherlands,
Germany and Spain. The first consumption room
was opened in Berne, Switzerland in 1986. In the
early nineties, the first consumption rooms were
opened in the Netherlands and Germany, while in
2000 the first was opened in Spain. There are no
consumption rooms in Ireland. 
In a consumption room, the use of drugs is
supervised by staff, who also give advice on risks,
educate clients about safer drug use techniques
and provide emergency help in case of overdose
or other adverse reactions. 
General admission criteria are that clients are
regular or dependent users of heroin or cocaine
and over 18 years old. Occasional or first-time
users are excluded. Access controls to
consumption rooms are strict, and in many
services personalised user cards are issued after
formal registration. In some cases, the number of
cards is limited to prevent overcrowding. Use of a
facility is sometimes restricted to local residents to
limit the influx of drug users from other cities.
House rules prohibit drug dealing and specify
basic hygiene requirements and safety procedures.
Consumption rooms do not advertise, and staff do
not help clients inject. 
On entry, staff ensure that potential service users
meet the admission criteria and make them
familiar with house rules. After receiving sterile
equipment, clients can use the facility, usually for
about 30 minutes (this period applies to facilities
that are predominantly used by heroin injectors;
cocaine injectors usually require less time). Inside
the supervised consumption area, a staff member
makes clients aware of health risks and dangerous
modes of consumption, observes during
consumption and provides safer use advice, for
example, on injecting techniques. Other staff are
available to provide immediate help in case of an
emergency. As most consumption rooms are
integrated into wider drugs services, many clients
also use other services available on site.
Risks and benefits
According to the author, the expected benefits of
consumption rooms are: 
■ decreased high-risk drug use; 
■ decreased morbidity and mortality among the
target population;
■ increased uptake of health and social care
including drug treatment; 
■ reductions in public drug use and
neighbourhood nuisance.
Because consumption rooms target those who are
not ready for treatment, a major function is to
offer other survival-oriented services, including
basic medical care, food, drinks, clothes and
shelter. The rationale underlying this function is
that drug users, as long as they cannot or do not
want to stop drug use, should be enabled to
survive in the hope that they may at some later
stage be able to give up drug use.
The possible risks of these facilities are that their
presence: 
■ encourages increased drug use; 
■ initiates new users;
■ makes drug use more acceptable and
comfortable thus delaying initiation to
treatment;
■ increases public order problems by attracting
drug users and drug dealers from other areas.
Effectiveness
Several studies have examined the positive and
negative effects of this intervention. Hedrich
reviewed the available literature on the
effectiveness of consumption rooms and her
summary findings are presented in order of the
specific objectives of consumption rooms. 
Objective 1: Attract difficult to reach
drug users
Consumption rooms reach their defined target
population, including street users and older, long-
term users who have never been in treatment.
There is no evidence that they recruit drug users
into injecting.
In order to achieve adequate coverage and high
rates of regular use, it is necessary to provide
sufficient capacity relative to the estimated size of
the target population, to locate rooms on sites
that are easily accessible and to ensure that
opening hours are long enough to meet demand,
especially in the evening. Rooms set up to
facilitate drug-using sex workers also need to be
appropriately situated and remain open in the
evening and night.
Given the nature of the target population, it is
vital that the ‘house style’ encourages rather than
deters potential clients. This implies that staff need
to be sympathetic and non-judgemental towards
problematic, marginalised and sometimes difficult
clients, yet at the same time be clear and
consistent about admission criteria and house
rules.
Drug consumption rooms (continued) 
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drug services and
health and social
care. In so doing,
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social inclusion of
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problem drug
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Objective 2: Provide a safer injecting
environment
Consumption rooms achieve the immediate
objective of providing a safe place for lower risk,
more hygienic drug consumption without
increasing the levels of drug use or risky patterns of
consumption.
Health education at consumption rooms
encourages sustainable changes in risk-taking
behaviour by some clients and contributes to
reducing drug-related health damage among a
difficult to reach target group. 
Objective 3: Decrease the incidence of
infection associated with drug use
No conclusions can be drawn about the direct
impact on infectious disease incidence owing to a
lack of studies and methodological problems
associated with isolating the effect of consumption
rooms. 
Objective 4: Decrease the incidence of
drug-related deaths
Where coverage is adequate, consumption rooms
may make a contribution to reducing drug-related
deaths at a city level.
Objective 5: Increase access to social,
health and drug treatment services
Consumption rooms clearly increase access to drug
services and health and social care. In so doing,
they promote the social inclusion of a group of
extremely marginalised problem drug users.
Besides supervision of drug consumption, a range
of other services is usually delivered on site. Low-
threshold medical care and psychosocial
counselling services are especially well used and
contribute to the stabilisation of and improvement
in the somatic and psychological health of service
users.
Consumption rooms make referrals to further
services, including drug treatment. For frequent
attenders, in particular, the rooms act as a link to
the wider system of care. Only a small proportion
of clients use the facilities for drug consumption
purposes only. The majority at some point make
use of other medical, counselling and treatment
services.
It is possible that some clients become partly
dependent on the services provided through
consumption rooms. This is a fairly common
observation in many services dealing with
marginalised and problematic client groups. There
is, however, little evidence to suggest that
consumption rooms delay treatment seeking for
problem drug use by clients through making drug
use more ‘comfortable’.
The question of whether consumption rooms
conflict with treatment goals, in particular whether
they should allow clients in oral methadone
treatment to use the rooms for injection, is dealt
with in different ways. For example, in Germany,
methadone clients are excluded from most
consumption rooms; on the other hand,
Switzerland takes the pragmatic view that if
methadone clients are going to inject anyway it is
better that they do so in safe and hygienic
circumstances.
Objective 6: Reduce public drug use
and associated nuisance
Consumption rooms can reduce the level of drug
use in public. The extent to which this is achieved
depends on their accessibility, opening hours and
capacity to accommodate drug consumption that
would otherwise occur in public.
The location of consumption rooms needs to be
compatible with the needs of drug users, but also
to take account of the needs and expectations of
local residents. A reduction in the number of public
consumptions can contribute to improvements in
the neighbourhood by helping to reduce public
nuisance associated with open drug scenes.
However, facilities near illicit drug markets are not
able to solve wider nuisance problems that result
from these markets.
Police actions against drug markets and drug
scenes in other neighbourhoods may sometimes
increase public order problems near consumption
rooms. This implies that, if rooms are to contribute
to reducing public nuisance rather than be blamed
for aggravating it, there needs to be consultation
not only with local residents but also with police, so
that action to discourage open drug scenes does
not at the same time deter drug users from making
use of the facilities.
Consumption rooms have greater impact where
there is a political consensus that they are part of a
comprehensive local strategy to respond to drug-
use-related problems that acknowledges public and
individual health objectives as well as the need to
maintain an acceptable situation with regard to
order and safety in the community.
There is no evidence that the operation of
consumption rooms leads to more acquisitive crime.
There is small-scale drug dealing in the vicinity of
many services, which is not surprising given their
location.
Conclusions
According to the author, the evidence suggests that
the benefits of consumption rooms can outweigh
the risks. It is important to set this in the wider
context of problem drug use and of responses to it,
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and to be modest in claiming what consumption
rooms can or cannot achieve. In particular, it is
unrealistic to expect that they can:
■ prevent all public drug use;
■ persuade all clients to reduce risky drug use or
enter treatment;
■ in themselves be the major factor in reducing
morbidity and mortality;
■ solve wider problems of drug markets and drug
dealing.
The author states that the evidence suggests that
consumption rooms can only be effective, if they are:
■ established within the wider framework of a
public policy and network of services that aim to
reduce individual and social harms arising from
problem drug use;
■ based on consensus and active co-operation
between key local actors, especially health
workers, police, local authorities and local
communities;
■ seen for what they are – specific services aiming
to reduce problems of health and social harm
involving specific high-risk populations of
problematic drug users and addressing needs
that other responses have failed to meet.
This article provides a basic overview of the
evidence in relation to the provision of
consumption rooms. It is recommended, as a first
step, that individuals or organisations considering
introducing such facilities read the complete
review-document. (Jean Long)
■ 1. Hedrich D (2004) European report on
consumption rooms. Lisbon: EMCDDA.
This report is available on the EMCDDA website at:
www.emcdda.eu.int
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Legal issues in relation to consumption
rooms
The International Narcotics Control Board (INCB) is
responsible for reviewing whether drug policies
adopted by countries bound by the three
international drug control conventions, comply
with those agreements. The relevant treaties are
the 1961 United Nations Single Convention on
Narcotic Drugs, the 1971 UN Convention on
Psychotropic Substances and the 1988 UN
Convention against Illicit Traffic in Narcotic Drugs
and Psychotropic Substances.
Citing Article 4 of the 1961 Convention, which
obliges states to ensure that the ‘trade in, use and
possession of drugs’1 is limited exclusively to
medical and scientific purposes, the INCB states in
its annual report for 2003 that facilities ‘where
injecting drug abusers can inject drugs that they
have acquired illicitly’ are, ‘from a legal point of
view’2 in violation of the international drug control
conventions.
In Ireland, the Misuse of Drugs Act (MDA) 1977
and 1984 and the Regulations made thereunder
ensure Ireland’s compliance with its obligations
under international law. Section 3 of the original
Act renders it a criminal offence to be in possession
of a controlled drug. Section 16 prohibits the
smoking or other use of prepared opium3 or the
frequenting of a place used for the purpose of
smoking or otherwise using prepared opium,4 while
section 19 prohibits a person from knowingly
allowing another to possess illicit drugs on
premises under his or her control.5 Despite a
number of provisions within the legislation for the
Minister to grant exemptions to the law regarding
possession in certain circumstances,6 as things
currently stand, drug consumption rooms, where
drug users could consume drugs obtained illicitly,
would be in direct contravention of Irish domestic
law.
Despite criticism from the INCB, a number of other
state signatories to the UN conventions have
adopted various legal measures to facilitate the
establishment of drug consumption rooms. In
doing so, they have tested the application of
international law in this area.
In Switzerland, following the establishment of a
number of state-controlled consumption rooms, a
legal opinion commissioned by the Swiss Federal
Office for Public Health (FOPH) concluded that
such facilities did not violate Swiss law ‘as long as
the rooms improve the hygienic conditions under
which consumption takes place and provide
medical supervision and no drug dealing takes
place’.7 A further opinion commissioned by the
FOPH considered the legality of such facilities in
relation to the three relevant international treaties.
This opinion, carried out by the Swiss Institute of
Comparative Law, concluded that, in the absence
of any clear guidance in the treaties on the utility
of ‘public injecting rooms’ with regard to the
‘rehabilitation and social reintegration of drug
addicts in the short term and to the reduction of
human suffering and the elimination of financial
incentives for illicit traffic in the long term’, it must
be concluded that ‘state parties retain the freedom
to make their own policy choices on the tolerance
of Fixer-Stubli (public injecting rooms)’. 
Legal issues in relation to consumption
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Furthermore, it was argued, ‘State parties are not
obliged by the conventions to prosecute and
punish the possession and consumption of drugs
(other than those psychotropic substances listed in
Schedule 1 to the 1971 convention.)’
In this respect, Switzerland may be seen to be
relying on what is referred to as the ‘expediency
principle’.8 This arises under Article 3, paragraph 2
of the UN Convention of 1988 whereby each party
is obliged to establish drug possession for personal
consumption as a criminal offence ‘subject to its
constitutional principles and the basic concepts of
its legal system’. This principle is used by some
countries to discourage prosecution of certain
crimes, such as possession of cannabis for personal
use for example.
In a legal opinion commissioned by the Strasbourg-
based think tank, the Pompidou Group, Professor
Dr Brice De Ruyver argues that ‘there is no clear
guidance in relation to the compatibility of
injecting rooms with international law’ and that
countries may apply the ‘expediency principle’
when establishing drug consumption rooms ‘in
order to avoid violating international laws’. He adds
however, ‘that governments are not allowed to
invoke this expediency principle whenever they
would like to deviate from the international
provisions’. De Ruyver concludes that ‘inasmuch as
injecting rooms are extreme forms of risk reduction,
some doubts can appear about the fidelity to the
convention obligations’ which require a ‘loyal
enforcement’.9
In Germany in 1993, an assessment of the legal
implications of supervised injecting facilities
commissioned by the health authorities of the city
of Frankfurt concluded that ‘the operation of such
facilities was not a punishable offence either under
any German laws or according to UN conventions,
provided that the sale, acquisition or passing on of
drugs/narcotic substances are not tolerated and
that hygienic, stress-free and risk-reduced drug
consumption is ensured through adequate care and
control’.7 The issue remained controversial in other
parts of Germany however. Consequently, in April
2000, the German parliament introduced an
amendment to the narcotics legislation which now
leaves it to the discretion of individual states
whether or not to issue such facilities with a
licence. Licences, where they are granted, are
generally contingent on compliance with a range of
minimum standards defined by law. These
standards relate to such measures as, for example,
adequate medical standards, the availability of
abstinence-oriented follow-up counselling,
measures to prevent criminal offences other than
possession of drugs for personal use from occurring
in or surrounding such premises, restrictions on the
age, type of drug and level of addiction of the user
attending the facilities.
In the Netherlands, legal guidelines issued in 1996
clarified that the possession of drugs in
consumption rooms is tolerated ‘provided the
facilities fit into the local policy framework defined
by the local triumvirate of mayor, police and public
prosecutor’.7 In Spain, supervised injecting rooms
operate on the basis of local public health
regulations.
In Sydney, Australia, and in Canada since 2003,
supervised injecting rooms operate on the basis of
scientific trials or pilot programmes which must
comply with ongoing evaluations and specific
licensing conditions in order to continue in
operation.
It has been argued that, as harm reduction
strategies, including drug consumption rooms,
become an increasing element of policy in a
number of states, so they have the potential to
become increasingly acceptable under the UN
treaties. Following a recent review of the UN drug
conventions regime and alternatives for reform,
Andenas and Spivak concluded that ‘the preferred
approach is one that is premised on collective
action by a group of countries with a shared reform
agenda. Such collective action paves the way for
various legal techniques which provide potentially
wide scope for modifying the drugs Conventions’.10
However, with regard to drug consumption rooms,
the preconditions established in specific countries
will determine whether these strategies qualify as
legitimate harm reduction practices. A difficulty
which arises here however, is that, at present, there
is no clear consensus between states on what
precisely ‘harm reduction’ is. As the INCB highlights
in its recent report: ‘The conventions do not
contain, refer to or define ‘harm reduction.’11
(Johnny Connolly)
1. Article 4, subparagraph 1 (c), United Nations Single
Convention on Narcotic Drugs 1961.
2. International Narcotics Control Board (2004) Report
2003. United Nations Publications.
3. Section 16 (1) (a) Misuse of Drugs Act (1977)
4. Section 16 (1) (b) Misuse of Drugs Act (1977)
5. Section 19 (1) (i) Misuse of Drugs Act (1977)
6. Part III Misuse of Drugs Regulations (1988) 
7. This discussion of legal approaches taken in countries
where drug consumption rooms are in operation is
derived from Hedrich D (2004) European Report on
drug consumption rooms. Lisbon: EMCDDA pp.15–19.
8. De Ruyver B (2000) Legal (Pre) Conditions and control
mechanisms with regard to risk reduction. Strasbourg,
Pompidou Group P-PG/MIN/CONF (2000) 2.
9. Ibid p.14. 
10. Andenas M and Spivak D (2003) The UN Drug
Conventions Regime and Policy Reform. Legal opinion
prepared by the British Institute of International and
Comparative Law (BIICL).
11. International Narcotics Control Board (2004) Report
2003. United Nations Publications p.36.
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here however, 
is that, at present,
there is no clear
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between states on
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‘harm reduction’ is
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resources for researchers
In early 2004 the Department of Community, Rural
and Gaeltacht Affairs published a Critical
Implementation Path (CIP), containing the critical
implementation paths for all government
departments and agencies responsible for
completing the 100 actions contained in the
National Drugs Strategy. The document maps out
how each of the 100 actions is to be delivered.
Government departments and state agencies have
identified a wide array of tasks needed to complete
the actions, including reviewing current policies,
undertaking gap analyses, consulting on issues,
establishing best practice, developing guidelines,
producing policy frameworks and identifying
resource needs. No less than 17 working or review
groups are to be established to progress the work.
The CIP also records the obstacles that departments
and agencies have identified as they have moved
forward.
According to the target timeframes set out in the
CIP, 43 actions should have been completed, or
completed and ongoing, by the end of 2003; 35
actions are due for completion during 2004; and
22 actions are due for completion during the
remainder of the period covered by the strategy.
However, as the CIP is a plan, rather than a
progress report, it is difficult to confirm how many
actions have been completed or where slippage has
occurred. In the introduction to the document, the
authors note that the projections are dependent on
resources being available to deliver the actions.
The need for ‘each agency to prepare and publish a
critical implementation path for each of the actions
relevant to their remit by end 2001’ is identified in
the National Drugs Strategy as a key performance
indicator (KPI), contributing to the achievement of
‘an efficient and effective framework for
implementing the National Drugs Strategy’. An
associated KPI is the completion of ‘an independent
evaluation of the effectiveness of the overall
framework by end 2004’. This evaluation is
scheduled to be completed in two stages:
■ an Annual Report, reporting on the nature and
extent of the drug problem in Ireland and on
progress in achieving the objectives set in the
Strategy, due by mid-2004; and 
■ a Mid-Term Evaluation, measuring the Strategy’s
impact and effectiveness, due by the end of 2004.
It is expected that the CIP will feed into the
evaluation process. The Minister of State with
responsibility for the National Drugs Strategy, Noel
Ahern TD, stated in his foreword to the document:
‘Through the CIP, we can gain important insights
into the strengths and obstacles within the Strategy
and refocus our efforts, if necessary. … the Strategy
must be flexible enough to tackle any new
challenges facing it.’ (Brigid Pike)
1 Department of Community, Rural and Gaeltacht Affairs
(2004) National Drugs Strategy 2001-2008: Critical
Implementation Path. Dublin: The Stationery Office.
National Drugs Strategy – Critical
Implementation Path published1
National Drugs Strategy Mid-Term Review – submissions invited
The Minister of State at the Department of Community, Rural and Gaeltacht Affairs with
responsibility for the National Drugs Strategy, Noel Ahern TD, has called for submissions from
interested individuals and groups as part of the mid-term review of the National Drugs
Strategy. The mid-term review will enable priorities for future actions to be identified and a
refocusing of the Strategy, if necessary, for the remaining period up to 2008.
Submissions should reach the Department of Community, Rural and Gaeltacht Affairs 
by close of business on Tuesday 17 August 2004 and be addressed to:
Email: drugsstrategy@pobail.ie
Fax: 01 667 0824
Post: Drugs Strategy Unit, 
Department of Community, Rural and Gaeltacht Affairs, 
43–49 Mespil Road, 
Dublin 2.
Guidelines and further information are also available at email drugsstrategy@pobail.ie 
or on www.pobail.ie
Note: All submissions received are liable to be made publicly available and, in any event, 
will be accessible under Freedom of Information legislation.
In May 2004, the Pompidou Group of the Council
of Europe published a report on a European Project
that sought, through the use of advanced statistical
techniques, to enhance the interpretation of drug
treatment demand data.1 The results of such
statistical analysis increase the relevance of
treatment data to policy and practice. The project
was carried out between 2001 and 2003 and
involved 14 cities across Europe. Statistical
consultancy was provided by Carla Rossi (Rome)
and Colin Taylor (London) and the project was co-
ordinated by Michael Stauffacher (Zurich).
Descriptive analysis is the first step in obtaining a
thorough understanding of data and is a
prerequisite for advanced statistical analysis. During
the course of the project, guidelines were prepared
to facilitate the participants in applying the
advanced statistical techniques. These statistical
techniques permitted the identification of the
independent contribution of each factor associated
with injecting drug use, and the calculation of the
incidence of heroin misuse for all those who seek
treatment within a specific time period. The report
provides an example of each of these analyses.
During the project, the participants learnt some
important lessons. These include:
■ The quality of the data collected and entered is
the key to the validity of the reporting system. If
questions on the forms are incorrectly or
incompletely answered, then the accuracy of the
analysis is reduced. The authors report that this
requires repeated contact with service providers,
proactive training, protocols for completing the
form and prompt analysis of data.  
■ The full analytic capability of treatment data
and its potential to inform policy and practice
has never been realised. Since a large amount of
resources are invested in the collection of
treatment data, there is an onus on those
responsible for these reporting systems to provide
regular and comprehensive analysis of data.
■ Data that are analysed promptly and
comprehensively are more useful to policy
makers and service providers.  
■ The comprehensive interpretation of treatment
demand data cannot be done without
considering the other indicators of the drug use
in a region or country and the responses to it. 
The Pompidou Group has advocated the collection
of drug treatment data using comparable
procedures and criteria for the last decade or so.
Since 2000, the Pompidou Group’s focus in terms
of drug treatment data evolved from one of data
collection to one of data analysis and
interpretation. Now, under the new work
programme of the Pompidou Group for
2004–2006, emphasis is placed on how such data
can be used to help develop evidence-based
policies and practices. A Pompidou Group project
to examine the impact of treatment demand data
on policy and practice in Europe is currently under
way and is co-ordinated by Drug Misuse Research
Division of the Health Research Board. The project
is funded by the Irish Department of Health and
Children. (Hamish Sinclair and Jean Long)
1. Stauffacher M, Arpa S and Vassilev M (2004) Follow-up
project on treatment demand: tracking long-term trends.
Final report. Strasbourg: Council of Europe, Pompidou
Group.
The Pompidou Group advocates better
use of drug treatment data
Occasional Paper 10: Twice as many are
treated for problem alcohol use than for
problem drug use 
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In April 2004, the DMRD, in collaboration with the
South Eastern and Southern Health Boards,
published an occasional paper entitled Treatment
demand for problem alcohol use in the South Eastern
and Southern Health Board areas, 2000-2002.1 It is
the first publication that documents treatment
demand for problem alcohol use in community
settings and special residential services and
complements the data published in the annual
reports from the National Psychiatric Inpatient
Reporting System. 
The number of treated cases reporting alcohol as
their main problem substance is at least double
that reporting all other drugs combined in the
South Eastern and Southern Health Board areas
(Table 1), suggesting that alcohol is the most
common substance of abuse in Ireland.
In both health board areas, 40 per cent of those
reporting problem alcohol use had been treated
previously, indicating that this is a chronic health
problem. 
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In 2001 and 2002, one-fifth of treated cases in
both health board areas reported use of drugs
along with alcohol. Cannabis was the most
common drug used alongside alcohol. Previously
treated cases were more likely to use
benzodiazepines with alcohol than were their
newly treated counterparts.
There was an increase in the proportion of new
female cases seeking treatment for problem
alcohol use in both areas, though the increase was
higher in the Southern Health Board area.
The rate of new cases (incidence) seeking
treatment for problem alcohol use varied
throughout the seven counties included in the
study and merely reflected the level of service
provision in the area and participation in the
reporting system. 
This analysis demonstrates that it is possible to
collect reliable data on problem alcohol use
through the National Drug Treatment Reporting
System, and highlights that the exclusion of
alcohol from reporting systems leads to an
underestimation of problem substance use and
the workload of addiction services. 
The benefit of information on persons with
problem alcohol use is that it will permit planners
to rank problem alcohol use alongside other
public health priorities in the population and to
allocate appropriate resources to its management. 
There is momentum gathering that responses to
alcohol and illicit drug use should be integrated.
This is an issue that is being discussed by the ten
Regional Drugs Task Forces, which have been set
up over the last year. These data identify a clear
overlap between problem alcohol and drug use
and point to the need for an integrated approach
to the management of substance misuse. (Jean
Long)
1. Long J, Jackson T, Kidd M, Kelleher T and Sinclair H
(2004) Treatment demand for problem alcohol use in the
South Eastern and Southern Health Board areas, 2000 to
2002. Occasional Paper 10. Dublin: Health Research
Board. 
This report is available on the Health Research
Board website at www.hrb.ie 
Occasional Paper 10: Twice as many are
treated for problem alcohol use than for
problem drug use (continued) 
Table 1   Numbers (%) reporting problem substance use that attended
treatment in the South Eastern Health Board (SEHB) and Southern Health
Board areas (SHB), 2000 to 2002
Main problem 2000 2001 2002
substance
Number (%)
SEHB SHB SEHB SHB SEHB SHB
Alcohol 1010 (71.2) 719 (67.3) 1472 (76.7) 852 (61.0) 1498 (71.5) 1160 (64.2)
Drug 
(licit or illicit) 408 (28.8) 349 (32.7) 447 (23.3) 544 (39.0) 598 (28.5) 647 (35.8)
Total 1418 1068 1919 1396 2096 1807
Tracy Kelleher
In April Tracy Kelleher left the Drug Misuse Research Division after five years to take up a
new position with the National Cancer Registry of Ireland in Cork. Tracy worked as a
researcher on the National Drug Treatment Reporting System (NDTRS) and was the main
link between the NDTRS and the providers of drug treatment services throughout Ireland.
During her time with us, Tracy co-authored many publications and was the lead author on
an occasional paper Trends in treated problem cannabis use in the seven health boards areas
outside the Eastern Regional Health Authority, 1998 to 2002, which will be published in the
autumn.  Tracy will be remembered as a warm, positive and committed colleague and we
want to wish her every success and happiness in the future. 
Welcome to the eighth EDDRA (Exchange on Drug
Demand Reduction Action) column. The aim of this
column is to inform people about the EDDRA
online database, which exists to provide
information to policy makers and practitioners on
drug demand reduction actions across Europe and
to promote the role of evaluation in drug demand
reduction action. The database is co-ordinated by
the European Monitoring Centre for Drugs and
Drug Addiction (EMCDDA). 
In this issue we focus on the St Aengus Stay-In-
School Youth Project, which operates in Tallaght in
West Dublin. The project was included on the
EDDRA database in 2002 as representing good
practice in drug prevention in Ireland. Recent
developments suggest that the project is now
accepted as a model of good practice
internationally.
The project was set up in 1998 to maintain 'at risk'
young people, aged 10-15 years, from St Aengus
parish in Tallaght in mainstream education. The
underlying assumption of the project is that when
'at risk' children are maintained in mainstream
education, there is a reduced risk of their engaging
in substance misuse. The association between early
school leaving and drug use has been highlighted
in research, both in Ireland and the UK. Comiskey1
found among 112 early school-leavers in Ireland
that 51.1 per cent had used drugs prior to leaving
school, with 46.5 per cent of these reporting that
their drug use had affected them at least
sometimes while attending school. Research from
the Youth Lifestyles Survey in the UK showed higher
rates of drug use for truants and those excluded
from school, compared with those routinely
attending school.2
The St Aengus project, along with two other
European projects (one each from Portugal and
Austria), has recently been used in training
seminars on drug prevention and evaluation held
throughout Portugal. The three projects were used
as examples of good practice because of their clear
design and interesting evaluation. Over 150
Portuguese professionals in the field of prevention
attended the seminars, which were organized by
the Institute for Drugs and Drug Addiction. The
seminar participants worked actively with the three
project examples in group discussions, improvising
on their design, learning how to apply concepts of
operational versus specific objectives, discussing the
use of relevant evaluation instruments, reflecting on
the variables and instruments for a good project
description and evaluation. 
An evaluation of the St Aengus project in 20003
found that all those who had participated in the
project over the previous two years were still in
mainstream education. Project activities were
extremely well received by participants, reflected in
attendance rates of over 90 per cent at all activities.
The project’s annual report for 2001 showed an
increase in the number of parents attending
parents’ sessions and in those expressing
satisfaction with the projects activities.4 In addition,
the number of volunteers giving time to the project
had also increased. (Martin Keane)
1.  Comiskey CM and Miller RTH (2000) Young people,
drug use and early school leaving. A report submitted to
the Research and Development Committee,
Department of Education and Science. 
2.  Goulden C and Sondhi A (2001) At the margins: drug
use by vulnerable young people in the 1998/99 Youth
Lifestyles Survey. Home Office Research Study 228.
London: Home Office Research, Development and
Statistics Directorate. 
3.  Rourke S (2000) St Aengus Stay-In-School Youth Project:
a process evaluation. Dublin: Tallaght Local Drugs Task
Force. 
4.  St Aengus Stay-In-School Youth Project. Annual Report
2001.
More information on the St Aengus project and
other Irish projects in the EDDRA database can be
obtained from the EDDRA website at
http://eddra.emcdda.eu.int
Alternatively, you can contact the EDDRA Manager
for Ireland, Martin Keane, at the Drug Misuse
Research Division, Health Research Board, Holbrook
House, Holles Street, Dublin 2. Tel: 01 676 1176
Ext. 169; Email: mkeane@hrb.ie 
If you wish to contribute to the knowledge base of
good practice interventions by adding your own
particular project to the database, please contact
the EDDRA Manager for Ireland at the above
address. 
EDDRA Column 
National Documentation Centre on 
Drug Use
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The National Documentation Centre on Drug Use
(NDC) has continued the development of its
electronic library of research and policy documents
and is working on a range of new information
resources. Currently the NDC makes the following
resources available to users of its website and
special library: 
■ An electronic library containing more than 500
full text research reports, journal articles,
conference papers and other documentation
relating to drugs in Ireland. These can be read
or searched by visitors to the NDC website at
www.hrb.ie/ndc;
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■ More than 2,500 books and reports and an
extensive collection of specialist journals which
are available to library visitors;
■ A range of excellent online bibliographical
databases which can be searched by visitors with
the assistance of NDC staff;
■ A diverse and speedy system of inter-library
lending so that visitors can identify, order and
receive the documents most relevant to their
area of research all within a few days.
The number of visitors to the NDC website and the
volume of queries dealt with by documentation
centre staff have increased steadily since the end of
last year. More queries were made and more
people visited the website during March 2004 than
in any previous month. The documentation centre
is currently developing a number of new
information resources which will be available at the
end of the summer. These include:
■ An electronic book with table of contents which
will make a major update on the drugs situation
in Ireland available to website visitors;
■ A directory of researchers in the drug field in
Ireland and a database of ongoing research and
evaluation in this area;
■ A revised News section will make news, new
publications and information on policy
development almost immediately available
through the website’s front page;
■ A simplified search option, by which visitors to
the web site can carry out database searches
simply by selecting from a list of subject
headings.
In developing its collections, the documentation
centre has worked very closely with staff of the
Drug Misuse Research Division. The DMRD’s
extensive collection of Irish research documentation
formed the basis of the NDC library collection. This
original collection has now been catalogued and is
available to visitors to both the website and the
NDC library. 
The DMRD’s monitoring of the drugs situation in
Ireland and its extensive international connections
have been of considerable help to the NDC in the
identification and acquisition of appropriate local
and international material.
Current Research and Evaluation
Database
The National Documentation Centre will shortly
begin to compile a database of ongoing research
and evaluation in the drugs area in Ireland. This
database will be a valuable information resource for
both researchers and those commissioning research
and evaluation work. The documentation centre is
also creating a directory of researchers and
evaluators which will contain details of research
interests and projects which the researcher or
evaluator is currently involved in. 
In order to ensure that the information on the
database and directory is accurate and
comprehensive, online forms which researchers and
evaluators can use to provide details of their work
will shortly be available on the NDC website. These
forms are short, easy to complete, and will allow
researchers and evaluators to create a thorough
and informative record of their work. The database
compiled from information provided in these forms
will be made available on the website later this
year. (Brian Galvin)
For further information on these information resources
contact the National Documentation Centre on Drug Use,
Health Research Board, Holbrook House, Holles Street,
Dublin 2. Tel: 01 676 1176; Email: ndc@hrb.ie or visit the
website at www.hrb.ie/ndc
National Documentation Centre on 
Drug Use (continued) 
From Drugnet Europe
Four new synthetic drugs under EU control
Cited from Alain Wallon and Roumen Sedefov,
Drugnet Europe No. 45, January–March, 2004
The Council of the European Union has adopted a
Decision defining four new synthetic drugs as
substances to be placed under control measures
and criminal penalties in the EU Member States. …
All four drugs, 2C-1, 2C-T-2, 2C-T-7 and TMA-2,
are amphetamine derivatives and have
hallucinogenic and stimulant properties. Although
there have been no reported cases within the EU of
death or poisoning due to these drugs, they are
believed to carry similar risks to other
hallucinogenic drugs that are already listed under
Schedules I or II of the 1971 UN Convention on
psychotropic substances.
Following the publication of the decision in the
Official Journal of the European Union, and in line
with their national laws, EU Member States have
up to three months to introduce measures to
control the four drugs, in compliance with their
obligations under the 1971 UN Convention on
psychotropic substances.
Progress in the key indicator 
‘drug-related deaths’
Cited from Julián Vicente, Drugnet Europe No.
45, January–March 2004
The EMCDDA expert group on population statistics
on drug-related deaths held its most recent annual
meeting on 11 and 12 December last year. The aim
of the meeting was to consolidate the
implementation of this key indicator by reviewing
progress in each country, assessing the quality of
the annual summary data (Reitox tables) and
developing technical training for full application of
the drug-related death protocol for a forthcoming
detailed data collection. … 
The forthcoming data collection (detailed
aggregated data) builds on previous projects and
aims to validate the key figures reported annually
by countries, to analyse national application of ICD
classifications and to allow further analysis at
national and EU level. 
Prevalence estimation: cutting-edge work
needs further investment
Cited from Luke Wiessing, Ludwig Kraus and
Carla Rossi, Drugnet Europe No. 45,
January–March 2004
The latest EU-wide expert meeting on estimation of
the prevalence and incidence of problem drug use
… concentrated on (1) how to further refine the
current EMCDDA definition of problem drug use,
which is a relatively wide ‘umbrella definition’ that
includes several subgroups of problem users; (2)
how to obtain more and better estimates of the
prevalence and incidence of problematic stimulant
use; and (3) the urgent need for more and
repeated local estimates as a necessary ingredient
of improved national estimates. It was
acknowledged that the multivariate indicator
method (MIM) can provide powerful syntheses at
national level but cannot be used in the absence of
multiple high-quality local estimates (preferably
obtained by capture–recapture based on three or
more data sets). New incidence estimates from
Austria, Italy and Spain presented at the meeting
suggest that there is important variation over time
in the initiation rates of new opiate users, providing
further evidence for the epidemic nature of
problem drug use. 
Drugnet Europe is a newsletter published by the
European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA). The newsletter is published
four times a year in Spanish, German, English,
French and Portuguese. An electronic version of
Drugnet Europe is available from the EMCDDA
website at www.emcdda.eu.int
If you would like to receive a hard copy of the
current or future issues of Drugnet Europe, please
contact Mary Dunne, Drug Misuse Research
Division, Health Research Board, Holbrook House,
Holles Street, Dublin 2, Tel: 01 676 1176 Ext. 127;
Email: mdunne@hrb.ie
From Drugnet Europe (continued) 
Drugs in Focus - Policy Briefings
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No. 12: Evaluation of the European
Union’s strategy and action plan
(2000–2004)
The EMCDDA’s twelfth Drugs in Focus policy
briefing was launched in May at the Dublin EU
drugs strategy conference, which started the ball
rolling for an EU strategy and action plan against
drugs post 2004. The final evaluation of the EU
drug strategy and action plan 2000–2004, to be
conducted by the European Commission with
technical assistance from the EMCDDA and
Europol, will be a key input into the development
of the new strategy and action plan. The
EMCDDA’s briefing paper on the evaluation process
highlights six points.
1. Importance of evaluation
Evaluation is essential for the ‘transparency and
legitimacy of public action’, helping to hold the
state accountable to its citizens for ‘what it does,
how it does it and the results it achieves’.
Evaluation also helps identify needs, improve
selection, planning and implementation of
responses and ensure a more rational allocation of
resources. 
2. Approach to evaluation 
The evaluation will look at the extent to which
actions laid down in the strategy are implemented,
the extent to which implementation of the plan
meets the objectives of the strategy, and the effects
of the strategy on the drug phenomenon. 
3. Innovative evaluation tool
Evaluating the effects of a particular policy on the
drug problem is both technically and scientifically
challenging. To rise to this challenge, the EMCDDA
and Europol have developed an information
baseline or ‘snapshot’ offering an overview of the
drug situation and policy measures at the outset of
the current action plan (1999). This will be
compared with a similar ‘snapshot’ at the close of
the plan (2004), enabling trends between the two
dates to be traced. 
4. Evaluation at national level
Most actions having an impact on the drug
situation are the sole competence of the EU
member states. Evaluation of the EU drug strategy
and action plan will only be fully effective if it
draws on evaluations carried out nationally. The
briefing urges member states to ‘develop their own
evaluation capacities’ with ‘appropriate resources’. 
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5. Political dimension of evaluation
There is more to evaluation than observation and
monitoring. It also involves a value judgement,
which presupposes prior agreement on the
underlying evaluation criteria and their respective
weighting. The briefing paper observes: ‘the
findings of evaluations are not always exhaustive,
do not remove all ambiguities and include a large
measure of uncertainty. Frequently they open the
door to several possible rational scenarios. An
intervention can be optimal from an economic
point of view, but costly from a social point of
view. Who should be the judge? Certainly not just
the scientists or evaluators.’
6. The next EU drugs strategy and action
plan
When European legislators set the objectives and
targets for the new strategy and action plan they
will have to take into account the results of the
evaluation exercise and monitor the priorities
adopted by means of a device providing adequate
indicators. They will also have to take into account
the change in perspective linked to European
Union enlargement. (Brigid Pike)
Drugs in Focus is a series of policy briefings
published by the European Monitoring Centre for
Drugs and Drug Addiction (EMCDDA). The
briefings are published three times a year in the 20
official languages of the European Union plus
Norwegian. An electronic version of Drugs in Focus
is available from the EMCDDA website at
www.emcdda.eu.int
If you would like to receive a hard copy of the
current or future issues of Drugs in Focus, please
contact Mary Dunne, Drug Misuse Research
Division, Health Research Board, Holbrook House,
Holles Street, Dublin 2, Tel: 01 676 1176 Ext. 127;
Email: mdunne@hrb.ie
Drugs in Focus - Policy Briefings (continued) 
Connecting research, policy and practice
On 6–7 April 2004 the Pompidou Group of the
Council of Europe held an international conference
in Strasbourg entitled ‘Connecting research, policy
and practice: lessons learned and challenges
ahead’. The conference provided policy-makers,
researchers and practitioners in the field of drug
prevention, treatment and criminal justice an
opportunity to reflect on the role of research in
policy and practice. For some twenty years now the
Pompidou Group has been active in the area of
drug epidemiology, developing and promoting a
range of drug indicators and methodological
approaches to examine the drug problem.
However, the work programme of the Pompidou
Group for 2004–2006 envisages a new role, that of
stimulating dialogue between researchers, policy-
makers and practitioners and acting as a catalyst
for evidence-based innovative approaches to drug
policy and practice. The conference was a first
attempt by the Pompidou Group towards the
development of strategic thinking on the
connection between research, policy and practice.
Prior to the conference, the Pompidou Group
commissioned Richard Hartnoll, in his capacity as a
former consultant in epidemiology for the
Pompidou Group and as the former head of the
epidemiology department of the European
Monitoring Centre for Drugs and Drug Addiction
(EMCDDA), to prepare a background paper. This
pre-conference paper reviewed what had been
achieved over the past twenty years in the area of
drug epidemiology, the current gaps in our
knowledge, and the opportunities available to
strengthen policy- and practice-relevant research.
The paper served as the basis for discussion by a
panel of international experts and participants at
the conference.
One of the main conclusions from the conference
was that there was a need for a strengthening of
policy-relevant research on drugs in Europe by
investment in a long-term strategy on research.
More emphasis on programme- rather than
project-based approaches was required and more
priority should be given to secondary analysis and
synthesis of existing data before embarking on 
new data collection. There was also need for 
'think tanks' of experienced researchers, policy-
makers and practitioners to offer detached
reflection and critical questioning. (Hamish Sinclair)
It is expected that Richard Hartnoll’s pre-
conference paper will be published by the
Pompidou Group before summer 2004. Copies will
be available in the National Documentation Centre
on Drug Use, Health Research Board, Holbrook
House, Holles Street, Dublin 2. Tel: 01 6761176
ext. 175; Email: ndc@hrb.ie
On 10 May 2004 the Minister for Justice, Equality
and Law Reform and President of the Justice Affairs
Council, Mr Michael McDowell, opened an
international two-day conference in Dublin to
discuss the future EU strategy on drugs. The
conference, entitled ‘EU Strategy on Drugs–The
Way Forward’, was organised by the Irish
Presidency in partnership with the Netherlands,
Luxembourg and United Kingdom forthcoming
Presidencies. More than 200 experts in the field of
drugs from the 25 EU member states, the three
candidate countries, all relevant EU institutions, as
well as other international bodies and
organisations, attended the conference. Addressing
the conference were speakers from the European
Commission, EUROPOL, the European Monitoring
Centre for Drugs and Drug Addiction and other
experts in specific drug-related fields.
The conference aimed to facilitate an exchange of
ideas between all participants and to agree
conclusions and recommendations on the main
elements of a future Strategy. The current EU Drugs
Strategy, for the period 2000–2004, will soon come
to the end of its term and the Justice and Home
Affairs Council will be invited to approve a new
Strategy for 2005 onwards. To facilitate discussion,
workshops were organised under the thematic
fields of demand reduction, supply reduction,
international co-operation, and information and
evaluation. In each workshop, four strategy
priorities proposed by the organising committee
were discussed with a view to reaching a consensus
on the main priorities for the new Strategy.
It was generally agreed that the new Drugs
Strategy should be based on a balanced and
multidisciplinary approach, on scientific evidence,
on respect for the principles of subsidiarity and
proportionality, and on providing added value in
relation to activities that are undertaken at national
level. Furthermore, the future Action Plan resulting
from the new Strategy should contain measurable
targets, and specific time-bound actions that can
be monitored and evaluated.
The Dublin conference was one of a number of
inputs to the preparation of the new Drugs
Strategy. Another will be the final evaluation of the
current EU Drugs Strategy 2000–2004 and its
Action Plan. The aim of the final evaluation, under
way at the European Commission, is to assess how
far the activities identified in the Action Plan have
been achieved, and how far that achievement has
met the objectives of the underlying Drugs
Strategy. It also aims to assess the impact of both
on the drug situation in the EU. The final evaluation
is expected by the end of October 2004.
At its meeting on 8 June 2004, the EU Council for
Justice and Home Affairs welcomed a report by the
Irish Presidency on the main elements discussed at
the Dublin Conference. (Hamish Sinclair)
International conference on the future
EU Drugs Strategy
Crack Cocaine, Epidemiology, Services
and Treatment Conference 
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On 10 May 2004, a crack cocaine conference was
held by the North West Wales NHS Trust in the
historic town of Caernarfon on the Welsh coast.
The conference was held in response to the
increasing number of crack cocaine users entering
treatment throughout the United Kingdom and the
perceived lack of services available to them. The
conference provided an opportunity for service
providers, project workers, researchers and other
people working with drug users to increase their
understanding of the issues surrounding the use of
crack cocaine. The speakers at the conference
shared their broad range of experiences with
attendees. 
The conference was divided into three sessions. 
Session one began by outlining the
physiology of crack cocaine use. 
■ Dr Chris Thorpe, a physician from the North
West Wales NHS Trust, spoke about the feelings
of euphoria, excitement and increased motor
activity experienced by an individual when using
crack cocaine; 
■ Dr Jim O’Toole, the Director of Substance
Misuse North West Wales NHS Trust, went on to
report on the risk behaviours associated with
crack cocaine, such as having unprotected sex
and sharing both injecting and smoking
equipment.
The afternoon session focused on patterns
of cocaine use from a criminal justice
perspective. 
■ Sgt Dewi Roberts, from the North Wales Police
force, stated that there are between 15,000 and
45,000 crack cocaine users in the United
Kingdom. Forty to fifty tonne of cocaine powder
is imported annually and police and customs
seize approximately one-fifth of it; 
■ Nino Maddalena, the Criminal Justice Manager
of the National Treatment Agency (NTA),
described the growing crack problem in the
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United Kingdom and said that the incidence of
crack use is generally under-reported.
The evening session concentrated on service
provision and effective approaches to
treatment. 
■ Aidan Gray (Advisor to the NTA) and Daniel
Taegtmeyer (Blenheim Project West London)
described methods of developing and delivering
services for crack cocaine users and the
treatment options available to them. They
emphasised that in order to develop appropriate
crack cocaine services it is necessary to: identify
the barriers that exist in preventing the
establishment of such a service; to ascertain local
trends and uses; and to identify effective
approaches to tackle the issue. 
The topics discussed at this conference will be
examined in more detail in Drugnet Ireland 12. The
research findings, practices and service provision for
crack cocaine users in the United Kingdom will be
compared with those in Ireland and suggestions
will be made on how to improve treatment services
for crack cocaine users in Ireland. 
Crack Cocaine, Epidemiology, Services and
Treatment Conference (continued) 
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Books
Drug users in society
Neale J Palgrave 2002
ISBN 0 333 91262 4
This book is one of a number of publications
resulting from a research project funded by the
Health Department of the Scottish Executive to
investigate drug users’ views and experiences of
non-fatal illicit drug overdose. It takes the approach
that, ultimately, the problem of drug misuse can
never be fully understood without a clear
appreciation of the motivations and life
circumstances of those individuals who become
involved in drug taking. The introductory chapter
describes in some detail the research design and
methods used. Chapter 1 provides a description of
opiates and their effects, considers how opiate
misuse has evolved as a social problem, and offers
an overview of policy responses in the US and the
UK.
The central part of the book is based on data
collected from in-depth interviews with 200 opiate
users living in Scotland. The respondents included
men and women, teenagers and older addicts,
novice drug users and those who had been
addicted for many years. In addition to discussing
their experiences of drug overdose, those
interviewed provided accounts of many other
aspects of their lives. Drawing extensively on drug
users’ own words, the book provides a candid
insight into what it means to be opiate dependent.
By interviewing addicts at different stages of their
drug-using careers and by discussing with them a
wide range of issues, the processes of obtaining
and using drugs are explored within the wider
context of personal biographies and daily routines.
Key topics considered include childhood
experiences; income, employment and educational
opportunities; crime and violence; housing and
homelessness; family relationships; prison life;
health matters; and drug treatments. Drug users’
statements are related to policy, service provision,
previous research, and theoretical debates in the
hope that this might increase understanding and
improve future responses to drug problems. 
Pieces of the jigsaw: Six reports addressing
homelessness and drug use in Ireland
Merchants Quay Ireland 2003  
ISBN  190279 407 9 
This book contains six reports of research studies
on aspects of homelessness and drug use in Dublin.
Five of the six studies were carried out within
Merchant Quay Ireland’s own programmes; four
were concerned with evaluating the services
provided by MQI, including methadone
prescribing, outreach work, and advice and food
centres; one set out to examine the health status of
female drug users. The sixth study was more policy
focused and reviewed the literature on the impact
of drug use on local communities. The research
work was carried out and the reports compiled
between 1999 and 2002. Contributors to this
volume are: Marie Lawless, Caroline Corr and
Gemma Cox.
The first chapter in the book reports on a pilot
project set up to examine the health status of
female drug users and their use of primary health
care, and to assess their healthcare needs. The
project was funded under the Health Research
Board’s Project Grants Scheme and ran for eight
weeks in 2001 at the MQI Contact Centre, The
investigation involved detailed medical assessments
and self-reported information. 
The next chapter reports on the evaluation of the
MQI methadone prescribing service in Dublin city.
The aim of this research was to measure the
service’s levels of effectiveness in terms of client
outcomes. Information on clients’ self-reported
behaviour was obtained by questionnaire at first
intervention and at follow-up 18 months later. The
research objectives included reviewing international
information on methadone maintenance and
defining the services provided by the methadone
prescribing service.
The other MQI services evaluated are the Outreach
Service, the Fáiltiú Information and Advice Centre,
and the Fáiltiú Food Service, all with the ultimate
goal of identifying their strengths and shortcomings
and improving their services to clients. 
The literature review is entitled ‘Managing Urban
Tensions’ and examines responses to drug-related
anti-social behaviour in Dublin’s inner city, and
presents an overview of best practice employed in
Europe.
Treating alcohol and drug abuse: an
evidence based review
Berglund M, Thelander S, Jonsson E (eds) Wiley-VCH
GmbH & Co KgaA 2003
ISBN  3 527 30682 X
This volume is the result of a project undertaken by
the Swedish Council on Technology Assessment in
Health Care (the official acronym is SBU) and its
editors include two members of the council. The
SBU was founded in 1987 to assess the
technologies and methods used in providing health
services and to identify treatment options that are
effective, not only medically, but also in economic,
social and ethical terms. 
The foreword to the book makes the point that,
despite the enormous resources spent on alcohol
and drug treatment programmes, there is still no
satisfactory evaluation of their effectiveness or of
the cost of the different alternatives. The project
described here set out to assess the range of
scientific literature on alcohol and drug treatment
by means of an integrated literature search, a
quality rating checklist and meta-analytic
techniques. Claimed as the most comprehensive
scientific review of its kind, it presents the findings
from more that 1,600 studies, including many
randomised control trials, on the effectiveness of
different treatments. The extensive results are
arranged in detailed tables, which may be searched
using the accompanying CD-ROM. 
The book consists of 10 chapters, and covers a full
range of topics in alcohol and drug abuse
treatment. It begins with a review of interventions
for hazardous drinking, followed by chapters on the
psychosocial and pharmacological treatment of
alcoholism. A chapter on the long-term course of
alcohol and drug dependence introduces a chapter
on psychosocial treatments for drug dependence
and three chapters on the pharmacological
treatment of opioid withdrawal, opioid
dependence, and cocaine dependence. A final
chapter reviews the literature on substance abuse
during pregnancy and the neonatal period. Three
appendices provide a list of the contributors and
scientific reviewers, the criteria used to rate the
quality of the articles reviewed, and the guidelines
employed to estimate effect size.  
Estimating the social cost of the illicit drugs
problem in Poland
Sieroslawski J and Boguslawa B  
Council of Europe  2004
The Pompidou Group recently published this report
of a cost estimation study on drug use in Poland.
The aim of the study was to verify the method of
social-cost calculation for illegal drugs designed by
Pierre Kopp and published by the Council of
Europe in 2001. Identifying and estimating these
economic costs could play an important role in
increasing the effectiveness of the social response to
the problems of addiction and illegal drug use.
Poland was selected for this study because of the
relatively extensive epidemiological data available
and because of the opportunity it presented to test
the feasibility of such a study in the Central and
Eastern European region. 
There are both private and public economic costs
associated with illegal drug use. For this study,
public costs were defined as the expenditure of
various institutions in response to the drugs
problem; private costs referred to spending by drug
users and their families and lost productivity due to
illness, death or imprisonment. Expenditure was
calculated using the attributable risk method, using
statistics and epidemiological studies. The method
of competent raters was used to estimate the
proportion of public expenditure attributable to the
drugs problem. The total social costs of illegal drug
was calculated on the basis that all financial
resources absorbed in dealing with the drugs
problem could be used elsewhere if the problem
did not exist. Lack of data meant that certain
specific costs, including those relating to treating
illnesses associated with drug use and injury
resulting from criminal behaviour, were not
included in the study. 
The study was based on a survey of 153 drugs
users in three rehabilitation centres in Warsaw and
Krakow in 2001.The total cost of illicit drug use in
Poland was estimated at €98.1million, about
0.06% of Poland’s GDP, or €2.5 per capita. The
state budget bears three quarters of this total cost.
Both this public cost and the private costs,
estimated at €47.5 million in total, are lower than
in other countries. The findings of the study show
that expenditure on supply reduction and
expenditure on demand reduction are roughly
equal. The authors recommend that the balance
should be shifted in favour of harm reduction.
The results of the study have been presented widely
both to the international research community and
to Polish policy makers.  
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Articles
The following are brief summaries of a selection of
articles published in international journals during
2004 relating to the drugs situation in Ireland or
written by Irish authors.
Prisoners’ views of injecting drug use and
harm reduction in Irish prisons
Long J, Allwright S and  Begley C
International Journal of Drug Policy 2004 April;
15(2): 139–149 
Drug misuse and hepatitis C are known to be
endemic in Irish prisons. Using a grounded theory
approach, this qualitative study sought to examine
prisoners’ views of drug injecting practices and
harm reduction interventions in Dublin prisons.
Thirty-one male prisoners were interviewed (16
injecting drug users and 15 non-injectors). Two
themes relevant to drug use practices emerged.
Respondents described increased health risks
related to injecting drug use during detention and
associated with a prison environment. These
included: the low availability of heroin which
encouraged a shift from smoking to injecting; the
scarcity of injecting equipment which fostered
sharing networks far wider than outside prison;
inadequate injecting equipment cleaning practices;
and the rent of needles and syringes in exchange
for the drugs. Both non-injectors and injectors
interviewed supported harm reduction
interventions in prison and felt that the range of
drug services available in prison should mirror those
currently available in the community, although half
opposed or had reservations about syringe
exchange in prison. Prisoners viewed their time in
prison as an opportunity to address substance
misuse related problems; health professionals
should not miss this opportunity.
Children attending addiction treatment
services in Dublin, 1990-1999 
Smyth BP and O'Brien M
European Addiction Research 2004; 10(2): 68–74
In Europe, adolescent substance misuse increased
during the 1990s. Ireland has among the highest
rates of substance misuse among schoolchildren in
Europe. This study sought to describe the socio-
demographic and drug misuse profile of children
presenting to addiction treatment services in Dublin
during the 1990s. Of the 9,874 individuals who
sought addiction treatment, 1,953 (20%) were
aged less than 18 years. There was a sharp increase
in the number of children after 1993. The main
drug of abuse was an opiate in 48 per cent of
cases. Compared to adults, the children were more
likely to be female and less likely to inject. As the
decade progressed the proportion of girls
increased, injecting was reported more frequently
and there was a dramatic rise in heroin misuse.
Child heroin users were more likely to be female
and to be homeless, compared to their adult
counterparts. This study highlights the need for a
dedicated service for child drug users in Dublin.
(Joan Moore, Louise Farragher) 
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July
5–9 July 2004 
AIDS / STD Prevention:
Designing Theory-based and
Evidence-based interventions
Venue: Maastricht University, The
Netherlands
Organised by/Contact:
Registration can be achieved by
filling in the registration form.
Registration forms can be
requested at the course secretariat:
Ms Anja Ronken
Tel: +31 (0) 43 38 82 941 
Email: anja.ronken@fd.unimaas.nl
www.interventionmapping.nl
Information: The summer course
will focus on developing theory-
based and evidence-based health
education and promotion
programmes for Aids prevention.
The emphasis of this course will be
on applying the Intervention
Mapping process to the
development of Aids prevention
programmes. Intervention
Mapping is a new process for the
creation of health education
programmes, in which the
educators are guided through a
series of steps that will assist them
in theory-based and evidence-
based intervention development. 
12–14 July 2004 
12th British Prison Drug
Workers’ Conference
Venue: Edinburgh, Scotland
Organised by/Contact:
Conference Co-ordinator
Tel: +44 (0) 20 8543 8333
Email: smaster@cranstoun.org.uk or
skucuk@cranstoun.org.uk
Information: Entitled 'Advancing
the Inclusion Agenda', the aim of
this conference is to promote
debate and facilitate the exchange
of information between those
working with drug users in prisons,
and to provide the opportunity to
network and contribute to
influencing policy development
within the field. 
September 
7 September 2004
Seminar: Drug Abuse: A
Perspective on Individual and
Community Rights
Speaker: Dr John O’Connor
Venue: Drug Treatment Centre
Board, Trinity Court, 30–31 Pearse
Street, Dublin 2 
Seminar Price:  €30.00 per
Seminar or €120.00 per Series (5
for the price of 4)
All places must be pre-registered,
full details available from: 
Tel: 01 648 8600   Fax: 01 648
8700
Email: seminars@dtcb.ie
www.addictionireland.ie
Information: Dr John O’Connor is
a consultant psychiatrist and
clinical director at the Drug
Treatment Centre Board, Trinity
Court / Beaumont Hospital and the Rutland
Centre. Specialising in substance misuse, Dr
O’Connor is widely published in this field.
16 September 2004
Towards a Comprehensive System for
Treating Alcohol-Related Problems
Venue: Edmund Burke Theatre, Trinity
College Dublin
Organised by / Contact: Fiona Clarke,
Addiction Research Centre, Goldsmith Hall,
Trinity College, Dublin 2
Tel: 01 608 3647   Fax: 01 608 3790 
Email: addiction.research@tcd.ie
21 September 2004
Seminar: Hepatitis C and Drug Users
Speaker: Dr Shay Keating
Venue: Drug Treatment Centre Board,
Trinity Court, 30–31 Pearse Street, Dublin 2 
Seminar Price:  €30.00 per Seminar or
€120.00 per Series (5 for the price of 4)
All places must be pre-registered, full details
available from: 
Tel: 01 648 8600   Fax: 01 648 8700
Email: seminars@dtcb.ie 
www.addictionireland.ie
Information: Dr Keating currently works
at the Drug Treatment Centre Board as a
medical officer and occupational health
physician.  His particular clinical and
research interest is the medical
consequences of intravenous drug use,
particularly hepatitis C infection.  He has
completed a pilot study into the on-site
treatment of hepatitis C in a specialist drug
treatment centre and has recently published
a booklet titled Hepatitis C: a guide for
drug users and their families. He is also a
specialist general practitioner working in the
areas of addiction and sexual health, in the
Eastern Region Health Authority and in
private practice.  
24–26 September 2004 
Crossing Boundaries: Implications of
Advances in Basic Sciences for the
Management of Addiction
Venue: Queensland, Australia
Organised by / Contact: Claire Norris 
Email:  addiction-conference@elsevier.com 
www.addiction-conference.elsevier.com
Information: The fifth international
conference on addictive behaviours will be
a two-day interdisciplinary conference
aiming to bring basic and applied scientists
together to discuss the opportunities for the
management of addictions that are
emerging from recent research. 
28 September 2004
Alcohol and Drugs in Sexual Assault
Venue: Manchester Conference Centre,
Manchester
Organised by / Contact: Iain Mclean 
Email: stmarys.sarc@cmmc.nhs.uk
www.stmaryscentre.org
Information: St Mary’s Centre announces
a conference for forensic physicians and
scientists, counsellors, nurses, health and
social service providers, the police, and
academics and practitioners interested in
rape/sexual assault or alcohol/drug use.
October 
5 October 2004
Seminar: Drugs and Alcohol: Should
we be approaching them so
differently?
Speaker: Dr Joseph Barry
Venue: Drug Treatment Centre Board,
Trinity Court, 30-31 Pearse Street, Dublin 2 
Seminar Price:  €30.00 per Seminar or
€120.00 per Series (5 for the price of 4)
All places must be pre-registered, full details
available from: 
Tel: 01 648 8600   Fax: 01 648 8700
Email: seminars@dtcb.ie 
www.addictionireland.ie
Information: Dr Joseph Barry is a specialist
in public health medicine with the Eastern
Regional Health Authority and senior
lecturer in public health at the Department
of Public Health and Primary Care, Trinity
College, Dublin. Dr Barry qualified in
medicine from UCC and has worked in
Dublin's drug services since 1989.  He has
been medical advisor to the National Drugs
Strategy Team since its establishment in
1996 and was a member of the Drug
Treatment Centre Board from 1993 to
2003. He is a member of the National
Advisory Committee on Drugs and of the
Strategic Task Force on Alcohol. He has
published extensively, nationally and
internationally, on drug-related issues.
19 October 2004
Seminar: Drug & Alcohol Use by Irish
Teenagers: From an Ireland of craic to
an island of crack?
Speaker: Dr Bobby Smyth
Venue: Drug Treatment Centre Board,
Trinity Court, 30-31 Pearse Street, Dublin 2 
Seminar Price:  €30.00 per Seminar or
€120.00 per Series (5 for the price of 4)
All places must be pre-registered, 
full details available from: 
Tel: 01 648 8600   Fax: 01 648 8700
Email: seminars@dtcb.ie 
www.addictionireland.ie
Information: Dr Bobby Smyth is a
consultant child and adolescent psychiatrist
working full time with adolescents who have
addiction problems. Based at the Drug
Treatment Centre Board in Trinity Court and
also with the South Western Area Health
Board, Dr Smyth completed general
psychiatry training in St John of God Hospital,
Dublin, before undertaking higher specialist
training on Merseyside in England. Currently
lecturing in Trinity College on addiction, Dr
Smyth previously sat on the executive
committee of the child psychiatry section of
the Royal College of Psychiatrists. Dr Smyth
currently is a member of the Department of
Health working party examining treatment
services for under 18s with serious addiction
problems in Ireland. Involved in addiction
research for past ten years, Dr Smyth has
published a dozen research papers in national
and international peer-reviewed journals.
21–23 October 2004
16th ELISAD conference and annual
meeting: Problematic Drug Use and
Lifestyles: Trends and Social
Representations
Venue: Florence, Italy 
Organised by / Contact: Mariella Orsi
Tel: +39 055 6263315 
Email: mariella.orsi@asf.toscana.it
Information: The theme of the conference
will be: Problematic use and lifestyles:
trends and social representations. In
particular, it will focus on phenomena such
as doping, gambling, eating disorders and
extreme risk.
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